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ABSTRACT

PROFILE OF SYSTEMIC TREATMENT WITH THE ANTIVIRAL LECTIN
GRIFFITHSIN IN GUINEA PIGS
Christopher Lynn Barton
May 25,2011

Griffithsin (GRFT) is a carbohydrate binding protein derived from the red
alga Griffithisia sp. that has been shown to effectively interfere with the cellular
attachment and infectivity of a number of viruses, including HIV-1. However, it is
currently unknown what impact systemic GRFT administration may have upon a
biological system.

For initial in vivo testing, we introduced GRFT into guinea

pigs (Cavia Parcel/us) via subcutaneous injection. Based on histological,
serological, and biochemical data derived from these experiments, GRFT is well
tolerated and maintained at physiologically relevant concentrations while
retaining its potent antiviral activity. Follow up in vitro testing included a number
of assays to assess GRFT's interaction with serum proteins and proteases. The
results confirm that GRFT is well tolerated by animals and maintains its antiviral
activity while simultaneously displaying a strong resistance to proteolytic
cleavage. Accordingly, GRFT is a strong candidate for further development as a
systemic anti-viral therapy.
v
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CHAPTER 1

INTRODUCTION
As the spread of viruses such as HIV, HCV, SARS and influenza
continues throughout the world, it is imperative that new therapies are fully
explored as potential weapons for stemming further transmission to uninfected
individuals as well as treating those already infected. HIV, affecting
approximately 33 million people worldwide, claims the lives of roughly 2 million
people per year [1]. HCV, the most common blood born infection in the US,
currently affects 3-4 million people, and is the leading cause of liver
transplantation [2]. A common structural feature among all of these viruses is a
dense, high-mannose N-linked glycan shield used to evade host immune
responses and stabilize viral envelope structure [3-5]. Accordingly, agents that
can target clusters of high-mannose glycans, typical of many viral envelopes, are
highly attractive candidates for potential antiviral therapies.
Among some of the most promising and potent topical anti-microbial
agents currently being investigated to prevent transmission of HIV, HCV, SARS,
and influenza are a subset of natural product derived lectins, carbohydrate
binding proteins which bind to the envelope glycoproteins of many viruses,
including HIV [6-9]. It is believed that these antiviral lectins can inhibit viral
transmission by selectively binding to the N-linked mannose moieties present on
1

the suriace of the viral envelope, thus preventing viral entry [7, 10-12]. Griffithsin
(GRFT), derived from the red algae Griffithisae sp., is one such lectin that is
currently under investigation as a potential vaginal microbicide [13]. In vitro
studies indicate that GRFT is a particularly potent HIV-1 entry inhibitor, with an
average EC so of 40 pM [14].
In addition to direct binding activity on free virions, it has been
demonstrated in vitro that antivirallectins, such as GRFT, can interiere with and
prevent cell-to-cell transmission of HIV between dendritic cells and macrophages
[13]. This ability to interiere with cell-to-cell viral transmission, as well as its ability
to effectively bind to the GP120 of HIV viral particles, warrants an investigation
into whether GRFT, in addition to its potential usage as a topical antimicrobial,
has utility as a systemic treatment for HIV.
The goal of this Master's thesis is to explore the potential of using GRFT
as a systemic therapy for enveloped viruses possessing high mannose N-linked
glycans by examining its systemic tolerability in guinea pigs, as well as
investigating some of the biological interactions that GRFT may encounter during
the course of systemic treatment. In Chapter 2, we assess GRFT's impact upon
metabolic organ systems and examine GRFT's serum persistence and anti-viral
activity when injected subcutaneously into guinea pigs. Chapter 3 explores
biochemical interactions that GRFT may have when introduced into systemic
circulation, including exposure to proteases and potential endogenous binding
targets. Finally, in Chapter 4, we analyze a viral resistance profile in the context
of HIV-1, examining glycosylation site changes that occur in a GRFT-resistant
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HIV isolate. Also described is the process by which HIV-1 enveloped pseudovirus
particles can be generated for examining GRFT's neutralization capacity.
Glycosylation States
Glycosylation is the process by which complex carbohydrate chains are
enzymatically added to organic molecules, such as proteins and fats [15]. These
carbohydrate chain additions serve as essential factors in maintaining proper
protein folding, increase protein stability, and contribute to their functionality [16].
Furthermore, glycosylation can greatly affect the water solubility of proteins,
given that the addition of the carbohydrate chains results in greater hydrophilicity.
In the case of viruses, glycosylation changes of external proteins and lipids can
greatly impact infectivity and viral fitness [17].
Occurring in either the golgi apparatus or the endoplasmic reticulum,
glycosylation can result in five different types of glycans: N-linked, O-linked, Clinked, glipiated, or phospho-glycans. The type of glycosylation most relevant to
the studies of GRFT are of the N-linked variety. Beginning with the addition of a
14 unit oligosaccharide precursor to an asparagine in a polypeptide chain, Nlinked glycosylation is signaled by either the sequence Asn-X-Ser or Asn-X-Thr,
where X can be any amino acid except proline [18]. As a structural precursor
common to most eukaryotes, the general branched carbohydrate chain contains
3 glucose, 9 mannose, and 2 N-acetylglucosamine molecules. Subsequently,
this branched carbohydrate chain is attached to a carrier molecule called a
dolichol, and transferred to the appropriate signal sequence (NXSfT) on the
polypeptide chain as it is translocated into the ER lumen [19].
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In addition to the varying linkage types available for glycosylation, there
are also differences in sugar compositions between glycans of the same linkage
type. These differences can result in the following sub-types of glycans: Highmannose, Hybrid, or Complex (Fig.1.1). These different subsets vary in the
amount of n-acetylglucosamine presented on the terminal portions of the sugar.
Whether an oligosaccharide will ultimately be High-mannose, Complex or Hybrid
is thought to depend on its accessibility to saccharide-modifying proteins in the
Goigi. High-Mannose glycans are a type of the N-glycan chain added to certain
asparagine residues of secreted or membrane proteins in eukaryotic cells,
containing 5-9 mannose residues [15]. High-mannose glycans are the initial
state of glycosylation for many glycans, with further editing occurring in the Goigi
which results in the formation of hybrid and complex glycans.
The final, terminal structure of the glycan after editing determines its
subtype. In the case of High-mannose glycans, no n-acetylglucosamines are
presented, resulting in exclusively mannose terminals (Fig. 1.1 A). In the case of
Hybrid glycans, enzymatic activity results in a carbohydrate chain that possesses
at least one terminal N-acetylglucosamine and at least one terminal mannose
(Figure 1.18). However, in the case Complex N-linked glycans, enzymatic
activity results in a carbohydrate chain containing multiple terminal Nacetylglucosamines (Fig.1.1 C). Deficiencies in certain key modification
enzymes can greatly affect glycosylation profiles. For example, reduction in
activity of cellular N-acetylglucosaminyltransferase I (GnT -I) - a glycan editing
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enzyme - can result in the production of almost entirely High-mannose type
glycans [20].

HIV-1
HIV-1, the virus responsible for AIDS, is a lentivirus belonging to the
retrovirus family of viruses [21]. Genetically, the HIV genome contains a total of
nine genes which can code for a number of viral proteins [22]. Three of them
encode structural and functional proteins essential for new virons: Gag, Pol, and
Env [22]. These three genes code precursor proteins which must be further
processed by cleavage before they become functional. Six other genes- tat, rev,
nef, vif, vpr and vpu-code for various viron processing mechanisms, including
cellular transport, assembly, and budding [22].
Gag encodes a precursor protein which is cleaved into four proteins:
matrix (p17), capsid (p24), neocapsid (p7), and p6 proteins [22]. This group is
synthesized as the p55 polyprotein which is subsequently cleaved by viral
protease into their individual components as well as two spacer proteins, p1 and
p2 [22]. These individual proteins are involved in viron core structure, assembly,
and budding.
Pol genes also code for the synthesis of a single unit precursor protein
which is cleaved to produce viral protease, reverse transcriptase and integrase
[22]. These proteins are packaged with new virons and are necessary for proper
viral protein function, cDNA synthesis, and cDNA integration into the host
genome [22].

5

The Env glycoprotein, which consists of gp120 and gp41, is also
synthesized as a 160kDa glycoprotein precursor protein which requires cleavage
into its individual proteins [22]. A signal peptide sequence on gp160 signals for

ER trafficking and post-assembly modification and glycosylation. After
modification, gp160 is cleaved into gp120 and gp41 by a furin-like protease [22].
From there transmembrane protein gp41 proteins are assembled into Env trimers
with gp120 molecules [22].
Two main proteins of interest in relation to lectin inhibition of HIV-1 are
gp41 and gp120. The outer viral envelope of HIV consists of phospholipids taken
from the host cell, whereas gp41 and gp120, encoded by the env genes of HIV,
form the viral envelope spike [23]. Structurally, gp120 trimers associate with
GP41 trimers in a non-covalent manner to form the envelope spike [23]. This
spike then interacts with the CD4 receptor present on target cells as well as
either the CCR5 or CXCR4 co-receptor molecules to initiate cellular infection
(Fig. 1.2) [24-27].
HIV Course of Infection
The functional course of viral infection of a susceptible T-cell follows a
characteristic pathway. First, gp120 present on the envelope of HIV binds with
the CD4 receptor molecule, which normally assists with the activation of T -cells
upon interaction with an antigen presenting cell (Fig. 1.2) [24, 28-29]. Upon
binding, the core of the gp120 trimer undergoes conformational changes,
resulting in greater flexibility and interaction with either the CCR5 or CXCR4 coreceptor, which are necessary for further steps in viral fusion [30-32]. Following
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co-receptor engagement, a conformational change occurs in the envelope spike,
altering the state of gp41 [33-34]. This conformational change allows the nterminal domain of gp41 to become exposed and inserted into the cellular
membrane [33]. Finally, this insertion induces a final structural change causing
the formation of a six-helix bundle, which provides the force necessary for
cellular fusion [33-35].
Upon successful cellular fusion, the capsid releases two copies of RNA as
well as the accessory molecules necessary for replication - reverse
transcriptase, integrase, and viral protease. Reverse transcriptase converts the
RNA copies to DNA [22]. Integrase functions to cleave the host DNA, integrating
the viral DNA into the host cell's genome [22]. Viral protease serves to cleave
precursor polyproteins into their functional units [22].
The mechanisms of productive systemic infection can vary somewhat by
point of entry. In HIV-1 transmission following mucosal exposure, cellular binding
of the viral particle to a susceptible cell is the first step in the process of HIV
infection It has recently been come to be understood that successful infection
often is accomplished by HIV isolates which have more compact variable loops
of gp120, with reduced numbers of N-linked glycans [36] . These viral particles
infect suboptimally activated memory CD4+ T cells in the genital mucosa [37-39].
Following low level replication, HIV-1 infects fully activated CD4+ T cells, leading
to migration of the virus to gut-associate lymphoid tissues where viral replication
is further amplified [40-41]. This leads to a high level viremia that establishes
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acute infection as well as a depletion of gut-associated T-cells possessing the
a4~7

gut homing integrin [36].
Vaginal transmission is the most common route of transmission

worldwide, as the majority of HIV-1 infected individuals worldwide are women. It
is believed that the cervix, which has a less protective columnar epithelium and is
rich in HIV-1 target cells, is a major site for HIV-1 transmission[42-44]. After
sexual intercourse, this area is exposed to seminal fluid, allowing contact
between virions and susceptible cells.
Receptive anal intercourse provides the greatest probability of mucosal
transmission [45-46]. This is likely due to two factors; a fragile layer of columnar
epithelium that can be damaged by the virus, and a high level of constitutively
activated T lymphocytes in the gut epithelium [45,47-49]. However, even in the
absence of epithelial damage, HIV-1 transmission in the anal mucosa can occur
through transcytosis or through infection of dendritic cells [50-51].
During penile transmission occurring during sexual intercourse, the route
of infection likely occurs via either the inner foreskin or through the penile urethra
[52-53]. The inner foreskin has abundant levels of HIV-1 target cells, including
CD4+ T cells, macrophages, and Langerhans cells [52]. Furthermore, the penile
urethra also has a population of CD4+ T cells and macrophages [52]. Thus,
during sexual intercourse, these surfaces become exposed to infected fluids,
exposing vulnerable tissues to potential infection.
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GP120 structure and glycosylation
As a protein produced by its eukaryotic host cells, the gp120 protein of
HIV is highly glycosylated, with an average of 24 glycosylation sites [54]. Recent
studies have shown that the glycosylation state of gp120 consists almost entirely
of the high-mannose variety [20]. It is currently hypothesized that this is due to
the inability of host editing proteins and a mannosidases to access the glycans
effectively, resulting in the inability to modify high mannose glycans into a hybrid
or complex form [20].
As with similar proteins, gp120 N-linked glycosylation relies on the signal
triplet Asn-X-Ser or Asn-X-Thr for the addition of the carbohydrate chains.
However, given the low fidelity of the HIV reverse transcriptase, there can be
great diversity in the number of high mannose glycans present on gp120 as the
virus evolves to avoid host defense mechanisms. Some studies have shown that
an increase in potential N-linked glycosylation sites can result in increased viral
fitness by reducing sensitivity to host produced neutralizing antibodies by
obscuring binding sites recognized by antibodies [55].
However, other studies have shown that decreases in glycosylation sites
may also playa role in viral fitness and infectivity. Studies of sequence data has
demonstrated that viral particles in a newly infected host have fewer
glycosylation sites as well as shorter variable loops [56-57]. These changes are
believed to facilitate the binding of the virus to the host receptor cells without the
interference by the carbohydrate chain additions. However, as the virus begins
replicating and is placed under neutralizing antibody pressure, an increase in
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glycosylation sites is observed. Accordingly, additions of glycosylation sites in
the gp120 may promote viral fitness in successive replication cycles by allowing
the virus to evade neutralizing antibodies by denying them access to previously
recognized epitopes.
Antiviral treatments
Many different pharmacological strategies and drugs are currently in use
for the treatment of HIV. These drugs include non-nucleoside reverse
transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease
inhibitors, integrase inhibitors, and fusion inhibitors. These therapies have
greatly increased the ability of an HIV infected individual to live close to a normal
life span. Prior to the advent of Highly Active Anti-Retroviral Therapy (HAART),
the expected survival span of an individual infected with HIV was 5 to 10 years.
Today, the life expectancy of a 20 year old starting antiretroviral therapy is an
additional 49 years [58]. The goal of HAART is to preserve immune function,
extend survival time, as well as suppress viral load to undetectable levels.
However, the complete elimination of HIV in those already infected seems
unlikely, if not impossible, due to the establishment of viral reservoirs within the
body which maintain a base level of infection, even while viral loads are deemed
undetectable. It is theorized that these viral reservoirs are the result of a latent
infection of long lived cells, or a suppressed but continual low level viremia in
which active cell to cell transmission continues to occur, or a combination of both
of those factors [59-63]. Accordingly, an agent that could further prevent cell-tocell transmission of HIV, and thus assist in reducing or eliminating viral
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reservoirs, would be an attractive complementary treatment to those whose viral
loads are suppressed to undetectable levels.
Entry Inhibitors
Among some of the newest agents currently being investigated as a
treatment of these viruses are entry inhibitors that can prevent viral fusion with its
target cell at various phases of the viral entry process. Entry inhibitors can act in
a number of ways, including presenting a physical barrier to viral fusion by
binding to the virus to prevent infection or by altering the cellular receptors
necessary for viral infection [13, 64]. Entry inhibitors can currently target a
number of proteins on either the virus or the cell. These targets include gp120 or
gp41 of HIV virions, the C04 receptor present on T-cells, or the CCR5 or CXCR4
co-receptors present on C04 cells.
T20, or Enfuvirtide, is an injectible peptide fusion inhibitor [65]. Enfuvirtide
is commonly used as part of a combination therapy when other therapies have
failed. Enfuvirtide acts by binding to gp41, preventing conformational changes
that are necessary for successful cellular infection (Fig. 1.20) [34]. As a 36
amino acid peptide, it mimics the HR2 fragment of gp41, and binds to the HR 1
region of gp41 [66-67]. Binding to the H1 region thus blocks formation of the six
helix bundle, the primary driving force for the final steps of cellular fusion process
[34]. In 2003, enfuvirtide was approved for treatment of HIV infection, due to
virological benefits seen when added as an adjunct antiretroviral regimen [68].
Maraviroc is a small molecule, CCR5 co-receptor antagonist, which is also
used as an entry inhibitor in the treatment of HIV-1 [69-71]. Maraviroc
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allosterically binds to the transmembrane cavity of the CCR5 co-receptor, thus
blocking its interaction with gp120 after gp120 has bound to the CD4 receptor
(Fig. 1.2C) [72]. This prevents subsequent binding steps and conformational
changes necessary for viral fusion with the cell.
Ibalizumab is a CD4-targeting antibody that is currently being examined as
an entry inhibitor [73-75]. While non-immunosuppressive, Ibalizumab binds the
CD4 molecule present on T -cells in the D2 region of the receptor (Fig. 1.2A) [7677]. This binding prevents conformational changes in the CD4 receptor
necessary for later steps in cellular infection. However, it does not interfere with
either the binding of MHC II molecules or the gp120 to the receptor, and thus
does not interefere with normal immune function [76-78].
One class of potential entry inhibitors are a subset of lectins, carbohydrate
binding agents. Generally, lectins are highly specific sugar binding proteins
which can agglutinate cells or precipitate conjugated sugars. Lectins can serve a
variety of purposes in plant and animal cells. In animals, they can serve to
regulate cell adhesion and by recognizing carbohydrates exclusively present on
pathogens. For example, mannose binding lectin is a serum protein which plays
a role in innate immunity by binding to pathogens, resulting in activation of the
complement system or opsonization of the pathogen [83].
Antivirallectins are a subset of lectins which bind to the envelope glycans
of many viruses, including HIV and HCV [7]. This subset includes Concanavalin
A, Cyanovirin, and Actinohivin [12, 79-80]. While different lectins have different
carbohydrate targets, it is believed that antivirallectins effective against HIV

12

infection inhibit viral transmission by selectively binding to the N-linked highmannose glycans present on the surface of the trimeric gp120 spike, thus
preventing cellular fusion (Fig. 1.28) [7]. It has also been theorized that crosslinking and aggregation of viral particles may also be an additional and equally
vital mechanism of viral inhibition [81].
Despite their promise as potential neutralizing agents for HIV and HCV,
lectin treatment can present a challenge. Aside from potential side effects due to
mechanism of drug action, the presence of proteinaceous drugs can induce
allergic reactions and anaphylaxis.

As foreign proteins, there is no opportunity

for central tolerance to their sequences to develop within immature T and 8 cells.
Accordingly, exposure to the protein can activate T and 8 cells, initiating an
immune reaction [82]. However, immune reactions can vary. Neutralizing
antibodies can also be generated which effectively bind the protein and facilitate
its degradation [82]. However, it is also possible that type I immediate
hypersensitivity reactions can be initiated which result in anaphylaxis [82].
Anaphylaxis is a potentially deadly reaction to immunogens wherein mast cells
are degranulated by the binding of IgE [82]. Multivalent binding of IgE to antigen
results in cross linking of FcRe, which activates degranulation [82]. This
degranulation results in the release of large amounts of histamine and TNF-a
[82].
Anaphylaxis has been observed in a number of proteinaceous drug
treatments. These drugs include Omalizumab, a monocolonal antibody
treatment for asthma, alpha galactosidase A for the treatment of Fabry's disease,
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and Rituximab for the treatment of leukemias and autoimmune disorders [83-86].
Fortunately, interventions can be used to delay and mitigate reactions to foreign
proteins. For example, treatment with methotrexate can delay immune response
to a-Galactosidase A therapy [87]. By depressing certain immune function, the
numbers of activated and replicating immune cells is decreased, resulting in a
decrease in potential production of antibodies. Nonetheless, as effective protein
therapies are employed, a full understanding of the potential immunological
consequences of drug administration will be valuable in devising strategies to
avoid such immune responses.
Griffithsin Structure and Mechanism of action
GRFT is a carbohydrate binding agent with high affinity for N-linked high
mannose glycans [13-14]. In solution, GRFT forms a domain swapped
homodimer with a total of 6 mannose binding sites, as determined by X-ray
crystallography of GRFT at 1.3A resolution [88-89]. Structural complexes of
GRFT with both man nose and N-acetylglucosamine have defined locations of 3
virtually identical carbohydrate binding sites on each monomer which use a
highly conserved GGSGG motif found in the loops of the protein [90]. This
sequence, as well as a dimeric domain swap forming the third binding pocket on
each side, provides amide groups which form the ligand binding sites. Upon
dimerization, GRFT's binding sites form an almost equilateral triangle on the
edge of the protein, creating two opposing surfaces for man nose binding [88].
GRFT's anti-HIV inhibitory capacity is mediated through its binding to the
high-mannose glycans present on the gp120 spike of HIV [14]. This binding
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interaction thus becomes a barrier to infection by preventing interaction between
the viral gp120 and the CD4 molecule of its target cells. Supporting this theory is
the fact that lectin-resistant isolates of HIV have been generated in the laboratory
by placing HIV under increasing concentrations of GRFT over successive
passages [4]. A genomic analysis of the envelope glycoproteins of these isolates
reveals that a number of glycosylation sites in the resistant viruses were deleted,
thus decreasing the number of potential binding sites for lectin activity.
To determine whether systemic effects of GRFT are the result of the
active site of GRFT or simply by the presence of foreign proteins, we have
developed a mutated form of the drug, GRFT1ec-, in which the carbohydrate
binding sites have been ablated by amino acid substitution (a substitution of
asparagine for aspartic acid residues in the binding pockets). While structurally
similar to mannose-binding GRFT in structure and sequence, this mutated form
does not bind high man nose glycans and demonstrates no antiviral activity in
pseudovirus challenges.
In order for GRFT to be a viable systemic antiviral treatment, it must be
able to be efficiently and economically produced, maintained in blood serum at
safe and therapeutic levels, and retain its anti-viral activity in the systemic
circulation. Prior work has demonstrated that GRFT is able to be efficiently and
economically produced in large quantities [91-92]. Additionally, prior studies
have demonstrated GRFT's weak immunogenicity and low induction of
inflammatory cytokines and chemokines[13, 92]. However, little study has yet
been conducted into the systemic tolerability of GRFT or the retention of its anti-
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viral activities in vivo. Furthermore, given that HIV is known to acquire drug
resistance when placed under drug pressure, insight is needed into the molecular
interactions that result in GRFT-resistant isolates.
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Figure 1.1. N-linked glycans - structural arrangement of subtypes. Schematic
depicting examples of different types of N-linked glycans. High Mannose glycans
(A) present exclusively mannose termini. Hybrid glycans (8) present a mixture of
mannose termini and GlcNac termini. Complex glycans (C) are devoid of
mannose termini.
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2. CCR5/CXCR4
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Figure 1.2. Steps of HIV-1 cellular entry highlighting sites of potential therapeutic
interventions. The above schematic demonstrates the steps of HIV-1 entry
relevant to different entry inhibitors including C04 attachment, co-receptor
binding , and cellular fusion. Potential therapeutic intervention points include: (A)
Ibalizumab binding site on the C04 molecule to prevent C04 conformational
changes necessary for co-receptor binding, (8) lectin binding sites for glycans
present on gp120 to prevent proper C04 interactions , (C) Maraviroc (CCR5
antagonist) binding site to prevent gp120/co-receptor interaction , and (0)
Enfuvirtide (T20) binding site to prevent conformational changes in gp41
necessary for the final stages of cellular fusion .
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CHAPTER 2
ASSESS GRFT'S SHORT TERM SYSTEMIC TOLERABILITY, ANTI-VIRAL
ACTIVITY, AND SERUM PERSISTENCE IN THE ABSENCE OF AN ANTIBODY
RESPONSE

INTRODUCTION
In this Chapter we will examine the systemic effects that subcutaneously
injected GRFT has upon the systemic physiology of female guinea pigs (Cavia
porcel/us). Given GRFT's demonstrated ability to block cell to cell transfer of

HIV-1, it is important to fully investigate any short term toxicological impacts that
GRFT has on a living system's physiology. Due to an inherently low background
HIV neutralizing activity in serum and blood, guinea pigs were chosen for the
animal model in this study so as to allow for full evaluation of GRFT's continued
neutralizing capacity after systemic introduction.
Given that the introduction of a foreign protein into a living system will
expose said protein to a vast number of proteases and potential degradatory
pathways, it was important to ascertain whether GRFT would: 1. maintain its
stability in serum; 2. maintain its anti-viral activity in an environment in which
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endogenous high mannose binding may occur; and 3. distribute into particular
organs or tissues.
For the experiments described in this chapter, GRFT, GRFr1ec-, or PBS
was injected subcutaneously into guinea pigs for a period of ten days. Drug
effects on Complete Blood Counts (CBC's), normalized organ weights, body
weight, and select serum chemistries were monitored for any changes in
experimental groups relative to PBS-treated controls. Additionally, histological
analysis of kidneys, spleens, livers, and vaginas was carried out on all animals to
document treatment associated pathologies as well as to determine whether
pathologies were due to protein presence or drug action. Finally,
hemagglutination assays were conducted to evaluate whether GRFT, as a lectin,
has the ability to cause erythrocyte aggregation. Potential aggregation of
erythrocytes could cause potential increases in red blood cell turnover, as well as
possibly make GRFT unable to be used in systemic circulation.
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MATERIALS AND METHODS

Twenty-six (26) female Hartley guinea pigs (Charles River), ranging from
6-8 weeks of age were chosen as the animal model given their low anti-HIV
neutralizing background in blood and serum. Six groups were formed,
consisting of 6 PBS treated animals (Groups 1a and 1b), 10 GRFT-treated
animals (Groups 2a and 2b) and 10 GRFT1ec- treated animals (Groups 3a and
3b).

Injection and Dosage
GRFT, manufactured by Kentucky Bioprocessing, LLC, was diluted in
Phosphate Buffered Saline (PBS, pH 7.4) to achieve a final concentration of
10mg/ml. GRFT1ec-, already at 9.5mg/ml, required no dilution before
administration. Subcutaneous injections of the appropriate drug solution or
vehicle (PBS) were conducted daily for a period of 10 days. Control group
members were injected with 1ml/kg/day PBS, while animals from test groups 2
and 3 received doses of 1Omg/kg/day of GRFT or GRFT1ec-, respectively. For
dosage determination and adjustment, all animals were weighed on days one
and five.

Sample collection
Group members from 1a, 2a, and 3a were weighed and euthanized twenty
four (24) hours after last treatment. All remaining group members were weighed
and euthanized 96 hours later. Euthanizations via cardiac puncture
exsanguination were performed under isoflurane anesthesia, followed by
thoracotomy. Vaginal lavage samples for Groups 1a, 1b, 2a, and 2b were taken
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via pipette using PBS prepared with 1 x Protease Arrest and EDTA (G
Biosciences) to prevent proteolytic degradation of GRFT. Kidneys, livers,
spleens, and vaginas were excised, weighed, and fixed in 10% formalin for 48-72
hours. After fixation, organs were placed in 70% ethanol and sent for slide
preparation, hematoxilin & eosin staining, and histological analysis.
Measurement of GRFT Concentrations
Serum was collected from blood samples by centrifugation and
concentrations of active GRFT were determined using a GP120 sandwich ELISA.
Briefly, 96-well Maxisorp plates were coated with 100 III gp120 diluted in PBS, at
a concentration of 250 ng/ml. After overnight incubation at 4*C, and subsequent
blocking of the plate wells with 3% BSA in 1xPBS-T, serum samples were
diluted (1: 10) in blocking buffer and incubated in the 96-well plate at room
temperature for one (1) hour. After washing in PBS-T, polyclonal rabbit antiGRFT primary antibody (1 :25000 dilution in blocking buffer) was incubated for 12 hours. After a second cycle of PBS-T washes, wells were incubated with a
HRP-conjugated goat anti-rabbit secondary antibody (1 :10000 dilution in blocking
buffer) for one hour. Following the one-hour incubation, wells were washed,and
100 III of SureBlue TMB Microwell Peroxidase substrate was added to each well
and developed in the dark for 10 minutes. The addition of 100 III of 1N sulfuric
acid was used to stop the reaction. Absorbance readings at 450 nm and 570 nm
were measured using a BioTek Synergy HT plate reader.
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Concentrations of GRFT1ecGRFT1ec- concentrations were not amenable to detection via gp120
sandwich ELISA given the inability of GRFT1ec- to bind to gp120. Accordingly, we
attempted to detect GRFT1ec-presence by SDS PAGE and Western blot. Serum
drawn from GRFT-treated guinea pigs and serum drawn from GRFT1eC--treated
guinea pigs were diluted 1:1 in sample buffer and separated by SDS PAGE on
an anyKD readygel (Biorad) for 20 minutes at a constant 200 volts. Transfer to
PVDF membrane was accomplished using a transfer buffer of 10% Methanol,
10mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) buffer. Transfer was
carried out at 200v for 25 minutes. After transfer to PVDF, the membrane was
blocked using a blocking buffer consisting of 5%non fat dry milk (NFDM) in PBS.
GRFT and GRFT1ec-presence was evaluated by incubating the membrane in a
rabbit anti-GRFT primary antibody (diluted 1:25000 in blocking buffer) for one
hour at room temperature. Following primary antibody incubation and rinsing in
PBS-T, the membrane was incubated in a goat anti-rabbit HRP-conjugated
secondary antibody (diluted 1:10000 in blocking buffer) for one hour at room
temperature. The membrane was washed in PBS-T and chemiluminscence was
detected by exposure of the PVDF membrane to X-ray film after addition of HRP
substrate.
Anti-HIV Activity
The anti-HIV activities of serum and vaginal lavage samples were
measured by our collaborator at Duke University, David Montefiori using a
pseudovirus neutralization assay. Antiviral activity was measured as a reduction
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in luciferase reporter gene expression as previously described[93]. 1050 values,
which represent antiviral activity, were reported as sample dilutions at which
relative luminescence units (RLUs) were reduced 50% compared to virus control
wells containing no serum or vaginal lavage sample. Virus stocks of molecularly
cloned Env-pseudovirus of Ou156.16 were prepared by transfection of 293T cells
and were titrated in TZM-bl cells as previously described. [93]
CBC and Serum Chemistry
At sacrifice, blood drawn via cardiac puncture exsanguination was
aliquotted into vials containing EOTA for complete blood count (CBC) analysis. A
complete CBC profile for each guinea pig in the control and GRFT-treated groups
was generated. Briefly, 20 III of whole blood was loaded into a Hemavet 950FS
and run according to manufacturer's directions. The CBC profile included
examination of the following: White blood cells (WBC), Neutrophils(Ne),
Lymphocytes (Ly), Monocytes (Mo), Eosinophils (EO), Basophils (Ba), Red Blood
Cells (RBC), Hemoglobin (Hb), Hematocrit (HCT), Mean Corpuscular Volume
(MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin
Concentration (MCHC), Red blood cell distribution width (ROW), Platelet and
Mean Platelet volume (MPV). Based upon the results of a pilot study on the
effects of GRFT on guinea pig serum chemistries, three serum chemistry profiles
were analyzed: serum albumin (Alb), alkaline phosphatase (ALKP), and amylase
(Amy). Serum samples from all treated animals was obtained as described
previously and tested for the selected chemistry values.
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Immunofluorescent Imaging
GRFT presence in unstained, formalin fixed tissue slide was visualized by
immunofluorescent detection. Organ slides were deparaffinized and hydrated by
duplicate and successive 10 minute incubations in Histoclear, 100% ethanol, and
95% ethanol. Slides were then subjected to antigen retrieval by immersion in
1mM sodium citrate buffer and high pressure heating using a 2100 Retriever
antigen retriever. Following a 10 minute PBS wash with agitation, slides were
blocked with 5% goat serum (v/v) in PBS for 15 minutes. Slides were then
incubated with polyclonal rabbit anti-GRFT primary antibodies at 1:100 dilution in
blocking buffer for one (1) hour. After washing in PBS, slides were incubated for
one hour with a FITC-conjugated goat anti-rabbit secondary antibody at a 1:500
dilution. After final incubation, slides were washed twice in PBS for 10 minutes
per wash. Slides were cover-slipped with Prolong Gold Anti-fade reagent with
DAPI . Slides were then imaged at 200x magnification using an Olympus CKX41
microscope and the appropriate fluorescence filter.

Hemagglutination
Hemagglutination activity of GRFT was evaluated. To test GRFT's
hemagglutination activity guinea pig erythrocytes (Innovative Research) were
washed with PBS to remove cell debris. Cell suspensions were spun down at
1000 x g for one minute and resuspended at a final cell concentration of 1-2% in
PBS containing 3 giL BSA and 1 giL sodium azide. Serial dilutions of either
Phytohemagglutinin (PHA) (positive control) or GRFT were mixed with an equal
volume of erythrocytes in a 96 well round bottom plate (total 100 IJUwell) and
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incubated for 1 hr at room temperature, followed by overnight incubation at 4*C.
Plates were then allowed to dry. Hemagglutination activity was determined by
visual examination of erythrocyte aggregation or dissemination versus controls,
with hemaggutination activity indicated by dissemination of blood cells in the
entire well as opposed to collection of blood cells into a single point.
Statistical Analysis
Statistical analysis was conducted using the Graph Pad Prism 5 program.
Groups were split between time points of day 11 (24 hour) results and day 15
(120 hour) results, reflecting date of euthanization. ANOVA was performed for
weight changes, organ weight differences, and serum chemistries between timematched groups. For the analysis of CSC data, for which GRFTlec• data was not
collected, t-tests between time-matched Control and GRFT-treated groups were
used. A p-value of <0.05 was deemed significant.
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RESULTS

Animal Morbidity and Mortality Observations
No animals were lost during the treatment period. No unusual behavior
during the treatment period was noted.
GRFT Serum Blood concentration
GRFT-treated animal sera contained measurable concentrations of GRFT
24 and 120 hours after last treatment. GRFT concentrations detected in serum
via a GP120-binding ELISA were plotted against their applicable test group (Fig.
2.1). PBS-treated control groups 1a and 1b showed no GRFT presence. Day
11-group 2a displayed an average GRFT concentration of 36 nM. Day 15-group
2b displayed an average serum GRFT concentration of 11.36 nM.
GRFT1ec- Serum Blood concentrations
GRFT1ec- was not detected by Western blot in serum from groups 3a and
3b (Img. 2.1). Serum from groups 2a and 2b were run in parallel, with GRFT
detected in those samples. Purified GRFT1ec- was run as a control to ensure that
the rabbit polyclonal antibody could detect the mutated form of GRFT. As
expected, a band was observed at 12.7 kDa.
GRFT Vaginal Wash Concentrations
Concentrations of GRFT in vaginal lavage samples were determined by
gp120-binding ELISA (Fig. 2.1). GRFT -treated animals displayed measurable
concentrations of GRFT in vaginal wash samples at both 24 and 120 hours after
last systemic administration, however GRFT was not detected in vaginal lavage
samples from PBS-treated animals. Vaginal washes from Group 2a animals
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displayed an average detectible GRFT concentration of approximately 9 nM.
Furthermore, vaginal washes from Group 2b animals continued to display
detectible GRFT concentrations of 2 nM.
Anti-HIV Activity
Antiviral activity was quantified using serum and vaginal wash samples of
animals treated with GRFT. HIV env-pseudovirus neutralization assays revealed
that GRFT retains its anti-HIV activity while in serum. Anti-viral activity was
plotted against the group from which serum was collected (Fig. 2.2). ID50 values,
representing anti-viral activity, were reported as the sample dilution at which
relative luminescence units (RLUs) were reduced 50% compared to virus control
wells containing no test sample. Sera from PBS-treated control groups displayed
a mean neutralization activity of less than 20. Sera from GRFT-treated animals in
Group 2a displayed a mean HIV neutralization capacity of 3277. Serum samples
from GRFT-treated animals in Group 2b displayed an average neutralization
activity value of 576.
Vaginal wash samples also displayed measureable anti-HIV activity,
however at much lower levels than those found in serum. Vaginal wash samples
from Group 2a were deemed to have a mean neutralization capacity of
approximately 70, whereas samples from Group 2b possessed a mean
neutralization capacity of approximately 40.
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Guinea Pig CBCs
No significant differences were observed on either day 11 or day 15 in the
numbers of the following categories: White Blood Cells, Neutrophils,
Lymphocytes, Monocytes, Eosinophils, Basophils, Red Blood Cells, Hemoglobin,
Hematocrit, Mean Corpuscular Hemoglobin, Mean Corpuscular Hemoglobin
Concentration, Platelets, or Mean Platelet Volume (Table 2.1). However, Group
2b red blood cell distribution width (ROW) and Mean Corpuscular Volume (MCV)
values were significantly different. Despite the statistically significant difference
in ROW values, all values for ROW were within normal physiological range for
guinea pigs, according to normal ranges for guinea pigs coded within the
Hemavet 950FS programming.
Alkaline Phosphatase, Amylase, and Albumin.
Analysis of serum chemistries revealed significant differences in serum
albumin and amylase levels on day 15 (120 hours post treatment). Bonferroni
post test comparisons between treatment groups vs. controls revealed that the
differences seen in ANOVA analysis were attributable to differences observable
in GRFT'ec- treated groups, which were significantly lower than controls.
Animal weight gain
Analysis of animal weight gains during treatment revealed differences in
percentage weight gain between groups. Animals in groups 2a (GRFT-treated)
and 3a and 3b (GRFT,eC-treated) experienced significantly less weight gain than
time-matched PBS controls. Animal percentage weight gain during treatment
was calculated and separated by sacrifice day and test group (Fig. 2.3). On day
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11, Group 1a control animals had experienced substantially greater weight gain
than both GRFT and GRFT1eC--treated groups (groups 2a and 3a). Furthermore,
GRFT1eC--treated animals in Group 5 continued to display significantly less weight
gain in comparison to PBS-control group 1b. However, group 2b no longer
displayed a statistically significant difference when compared against controls
when analyzed by Bonferroni post hoc test.

Organ weights
Liver, kidney, and spleen weights at time of sacrifice were analyzed for
significant change in relation to total body weight. Average organ weight- tobody weight percentages were plotted against test groups (Fig. 2.4). Liver
weights showed no significant difference on either day 11 or day 15. Results for
kidney weight were mixed, with no difference observed at day 11. However on
day 15 there was a significant difference amongst groups observed when
analyzed by two-way ANOV A. A Bonferroni post test between test groups vs.
control was conducted, showing a significant difference control and GRFT1ectreated groups. Spleen weight difference results were also mixed, with no
significant difference observed at Day 11. However, on day 15, G RFT -treated
groups displayed a statistically significant greater spleen to body weight ratio
when analyzed by ANOVA and Bonferroni post test.

Organ Histopathology and Imaging
Although there were diverse pathologies observed among all treatment
groups, no pathologies related to GRFT treatment were observed. Among all
treatment groups, notable pathologies included chronic pyelitis in the kidneys,
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extramedullary hematopoesis localized in the spleen, and a minimal or mild
chronic portal or periportal hepatitis in the livers.
Immunofluorescent Imaging

Immunofluorescent imaging of organ sections revealed a strong presence
of G RFT in G RFT -treated animals both 11 days and 15 days after treatment in
the kidneys and spleen (Image 2.1). GRFT appeared to be most concentrated in
the spleen, with presence also being observable in the liver, kidney, and vaginal
tissue 120 hour post treatment. GRFTlec • was not detectible in any organ tissue
tested.
Hemagglutination activity

GRFT's hemagglutination activity in guinea pig blood was analyzed.
Visual inspection of wells containing PHA, PBS, and GRFT were compared (Fig.
2.2). As expected, PBS did not show any hemagglutination activity. PHA, a
lectin with known activity, demonstrated hemagglutination activity in the 0.5
mg/ml (0.3

~M)

to 10

~g/ml

(78.1 nM) range. Comparisons between wells

demonstrated that GRFT possesses hemagglutination activity in guinea pig
erythrocytes in the 1mg/ml (41
concentrations below 100

~M)

~g/ml,

to 100

~g/ml

(4.1

~M)

range. At

GRFT did not appear to have any significant

impact upon erythrocyte agglutination.
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GRFT Concentrations (Serum)

GRFT Concentrations (Vaginal)

Figure 2.1 . Concentrations of GRFT in serum and vaginal washes of guinea pigs
treated with GRFT or PBS. Serum and vaginal washes from PBS and GRFTtreated Guinea Pigs was analyzed for GRFT presence. Nanomolar
concentrations of GRFT were detectible in both serum and vaginal wash samples
at 120 hours after last administration. Bars indicate mean concentrations with
standard deviation .
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Image 2.1. Western blot of guinea pig serum to determine persistence of
GRFT1ec-. Serum from GRFT-treated and GRFT1eC-treated guinea pigs was
diluted in running buffer and examined for GRFT or GRFT1ec- presence. At both

24 and 120 hours post cessation of treatment, GRFT was detectible in serum.
However, at no time point examined was GRFT1ec- detectible. From left, GRFT,
GRFT1ec-, and two GRFT-treated animal serum samples. Serum from GRFT1ectreated animals was run in lanes 5-9.

33

Neutralization Activity (Serum)

Neutralization Activity (Vaginal Wash)

Figure 2.2. Analysis of HIV neutralization activity of guinea pig serum and
vaginal wash samples. HIV pseudovirus neutralization was used to test samples.
Numbers represent test sample dilution required to reduce luminescence to 50%
of test wells containing no serum or vaginal wash sample. Dilutions under 20
were deemed to be non-neutralizing. Bars indicate mean concentrations and
standard deviation.
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CBC
Day 11

Category

Day 15
Group 1b

Group 2a

Group 1ai

Group 2b

N=3

Std.

N=5

Std.

Sig.

N=3

Std.

N=5

Std.

Sig.

WBC

4.92

2.43

2.15

0.23

ns

4.35

1.28

2.9

1.36

ns

NE

2.3

1.46

0.96

0.13

ns

1.67

0.45

1.01

0.42

ns

LV

2.49

1.11

1.14

0.28

ns

2.6

0.89

1.82

0.99

ns

MO

0.09

0.1

0.03

0.03

ns

0.07

0.03

0.06

0.04

ns

EO

0.03

0.02

0.02

0.01

ns

0.02

0.02

0.01

0.02

ns

BA

0

0.01

0

0

ns

0

0

0

0

ns

RBC

4.3

0.06

4.12

0.18

ns

4.75

0.21

4.37

0.22

ns

0.46

12.22

0.61

ns

•

.....

i

Hb

12.23

0.64

11.64

0.46

ns

13.1

HCT

38.3

2.31

36.12

1.47

ns

41.57

1.76

39.52

1.94

ns

MCV

00.'11

<t.

3

87.58

1.29

ns

87.53

1.7

90.4

0.52

*

MCH

28.43

1.33

28.26

1.52

ns

27.63

0.61

27.96

1.04

ns

MCHC

31.97

0.25

32.26

1.33

ns

31.5

0.26

30.94

1.11

ns

ROW

13.83

1.43

12.92

0.7

ns

14.13

0.29

1.".00

PLT

595.33

54.31

628.6

44.77

ns

677.33

11.93

659

34.26

ns

MPV

4.4

1.14

3.92

0.23

ns

3.57

0.12

3.84

0.24

ns

Hb

HCT

MCV

MCH

u.

*

Normal CBC Values
WBC
6.0-14.0

NE

LV

0.4-6.7 1.9-11.1

MO

EO

BA

RBC

0.0-0.7

0.0-1.0

0.0-0.1

4.4-6.0

MCHC

RDW

PLT

MPV

11.0-15.0 37.0-48.0 77.5-88.5 22.0-28.0

28.9-32.0 2.4-27.0 380-650 5.0-20.0

Table 2.1. CBC values for PBS and GRFT-treated guinea pigs. Whole blood
samples were analyzed. Values are group averages with standard deviation.
Two significant changes were observable in GRFT treated animals are denoted
by (*).
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Day 11

Day 15

Grp.

Grp.

Grp.

Grp.

1a

2a

3a

1b

Grp.

Grp.

St

2b

3b

N=3

Std.

N=5

Std.

N=5

Std.

Sig

N=3

d.

N=5

Std.

N=5

Std.

Sig

ALB

2.0

2.2

2.3

0.2

2.0

0.3

ns

2.4

0.2

2.2

0.3

1.9

0.2

*

ALK

166.3

36.7

249.2

61.9

207.6

39

ns

146.7

76

255.6

70

217.8

50.0

Ns

AMY

702.7

123

883.0

201

657.4

75

ns

817.3

81

820.2

141

629.6

75.8

*

Table 2.2. Select serum chemistry values for PBS, GRFT-treated, and GRFT1ectreated guinea pigs. Serum samples were analyzed for the above chemistry
values. Significant changes were observed in serum albumin and amylase levels
in GRFT

1ec

-

treated animals, with those animals displaying chemistry values lower

than controls.
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Figure 2.3. Mean whole body weight increases during treatment with PBS,
GRFT, or GRFT

1ec

-.

GRFT, GRFT1ec-, and PBS treated animals were weighed at

initiation of treatment and at sacrifice. Average percentage weight gain was
analyzed. Significantly less weight gain was seen in GRFT and GRFT1ec- treated
groups at 24 hours after treatment completion (day 11). GRFT1ec- treated animals
continued to display significantly less weight gain at 120 hours after treatment
completion (day 15). Bars indicate standard deviation, with significance denoted
by (*).
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Figure 2.4. Mean organ weight- to-total body weight percentages of treatment
groups. Organ weights were determined at sacrifice and normalized by total
animal weight. Analysis showed that no statistically significant differences were
observed 24 hours post treatments. However, 120 post treatment significant
differences in organ weights were observed. Bars indicate standard deviation
with significance denoted by (*).
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PBS

GRFT

Kidney

Liver

Spleen

Vagina

Image 2.2. Immunofluorescent imaging of organ tissues to examine distribution
and persistence of GRFT. Unstained organ tissue slides from 120 hours post
treatment were probed for GRFT and GRFT1ec- presence using rabbit anti-GRFT
primary and FITC-conjugated goat anti-rabbit secondary antibodies. GRFT was
still observable in kidneys, liver, spleen, and vaginal cross sections. Kidney
images at 400x magnification; all others at 200x magnification.
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GRFT

PHA

2.7 mg/ml

0.25 mg/ml

1.35 mg/ml

50llg/ml

0.5 mg/ml

51lg /ml

0.25 mg/ml

0.51lg/ml

50llg/ml

50 ng/ml

51lg /ml

5 ng/ml

0.51lg/ml

50 ng/ml

PBS

5 ng/ml

0.5 ng/ml

Image 2.3. Hemagglutination activity of GRFT on guinea pig erythrocytes.
Hemagglutination activity of GRFT on guinea: pig blood was analyzed.
Phytohemagglutinin (PHA) was used as a positive control. PBS was used as a
negative control. Comparison of wells shows that GRFT possesses
hemagglutination activity in guinea pig blood in the range of 1mg/ml (20.5I1M) to
10011g/ml (2 .05 11M). PHA possesses hemagglutination activity in the 0.5mg/ml
(0.15I1M) to 10 I1g/ml (39 nM) range.
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CONCLUSIONS AND FUTURE DIRECTIONS

Griffithsin persists in serum and maintains strong anti-viral activity while
simultaneously inducing few systemic changes - an increase in MCV, ROW, and
spleenomegaly -but displaying no treatment associated organ pathologies.
Nonetheless, GRFT does have observable hemagluttination activity in guinea pig
blood within the range of treatment doses. This activity may cause the red blood
cell variations seen in GRFT treated animals and may account for the
splenomegaly observed due to an increase in red blood cell turnover. However,
it is currently unclear whether these effects will be observed in other species.
Furthermore, in addition to it serum stability and retained anti-viral activity, GRFT
shows a wide distribution into organs and vaginal mucosal tissues. These
properties support the further examination of GRFT as a potential systemic antiviral therapy for HIV. Additionally, the translocation into vaginal mucosa may
indicate a potential use for GRFT as a pre-exposure prophylactic measure given
that GRFT can penetrate into vaginal transudate, which is typically low in protein
content.
Previous studies have indicated that while weakly immunogenic, an
antibody response to GRFT is possible as a result of chronic dosing. However, it
is unclear what impact an antibody response will have upon GRFT's serum
persistence, anti-viral activity, and systemic tolerance. We will evaluate the
effects of immune activation upon active GRFT serum levels and systemic
tolerance utilizing rat and mouse models. We will also generate serum
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thermograms of pre-immunized, passively immunized, and chronically exposed
animals to assess antibody response impacts on serum protein interactions.
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CHAPTER 3
CHARACTERIZATION OF BIOCHEMICAL INTERACTIONS OF GRFT BY
EXAMINING ITS IMPACT UPON SERUM PROTEIN PROFILES AND GRFTPROTEASE INTERACTIONS

INTRODUCTION
In this chapter we examine biochemical interactions that GRFT may have
within a living system. We used Differential Scanning Calorimetry (DSC) to
evaluate the interactions between GRFT and serum proteins in serum from
guinea pigs treated as outlined in Chapter 2. We also characterized human
serum spiked with GRFT. Given that GRFT persists in serum and remains active
after systemic administration, we tested the drug against a panel of biologically
relevant proteases to fully understand GRFT's proteolytic resistance and to
characterize potential degradation and metabolic pathways. Finally, we initiated
experiments using co-immunoprecipitation of GRFT in serum to identify potential
endogenous binding partners.
One method that has been applied to explore biochemical binding
interactions in serum or plasma is Differential Scanning Calorimetry (DSC).
Plasma consists of over 3000 different proteins but most are present in extremely
low abundance with 99% of plasma's proteomic mass consisting of 22 proteins
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[94-95]. DSC has been used to measure the denaturation profile, known as a
thermogram, of the most abundant proteins present in plasma for healthy
individuals as well as those suffering from a number of different diseases [96]. It
has been demonstrated that significant differences are apparent between the
healthy and disease thermograms presenting the potential for use of this
method in the clinical diagnosis of diverse disease states such as rheumatoid
arthritis, lupus erythematosis, and Lyme disease [96-100]. The changes in the
disease thermogram are proposed to be a manifestation of the interactome
hypothesis where low molecular weight proteins or peptides unique to a disease
state bind to the more abundant plasma proteins and alter normal interactions
between them [101]. DSC is extremely sensitive to changes in concentration of
protein components in a mixture as well as to binding interactions between
components making this a powerful technique to probe perturbations in the
plasma interactome [102]. Measuring a small protein's impact on the more
abundant plasma proteins can provide invaluable data to describe stabilizing and
destabilizing effects that a protein may have when introduced into a system.
Mechanistically, DSC measures small differences in heat flow from a sample and
a reference chamber as both chambers are heated at a constant rate over a
temperature range of interest [95, 97]. Differences in heat flow as a consequence
of thermal events occurring in the sample cell provide a characteristic curve, or
thermogram, in the form of excess heat capacity of the sample as a function of
temperature [102]. Every protein has a characteristic denaturation thermogram
reflecting a unique thermodynamic signature for the melting of the tertiary
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structure of that protein [100]. For a mixture of proteins, such as plasma, the
thermogram reflects the superposition of the denaturation thermograms of the
major protein components according to their relative concentration and the
presence of any binding interactions [100]. Observation of changes in the plasma
thermogram as a consequence of binding allows the quantification of binding
interactions through comparative shifts in denaturation temperatures of the major
plasma proteins [102]. For example, a protein ligand which prefers the denatured
state of a larger protein will result in a decrease in the denaturation temperature
of the larger protein once bound [96]. Thus, it is possible that a consistent and
significant change in a serum thermogram may be predictive of toxicity
associated with systemic treatment of GRFT by virtue of it is impact upon normal
interactions between endogenous serum proteins.
In addition to DSC thermograms generated, it was also necessary to
investigate GRFT's resistance to proteolysis. In particular, given its presence in
vaginal mucosa following systemic administration, GRFT's resistance to a
number of proteases in the Kallikrein family was evaluated. The Kallikrein family
of proteases are present in blood, vaginal secretions, and semen [103-104].
Furthermore, given GRFT's strong serum persistence, proteases such as
Trypsin, MMP-12, and elastase were also evaluated given their strong proteolytic
activity and systemic presence.
Finally, we began to examine whether potential endogenous binding
partners of GRFT were responsible for its long serum persistence. In particular,
hemagluttination assays in species other than guinea pigs were conducted to

45

expand upon the assays outlined and conducted in Chapter 2. Coimmunoprecipitation of GRFT that had been incubated in serum was used to
assess whether there are any endogenous binding partners for GRFT that can
be retrieved from serum.
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MATERIALS AND METHODS

DSC- Guinea Pig Serum Profiles
Serum samples harvested from guinea pigs injected subcutaneously with
PBS, GRFT, or GRFT1ec- were aliquotted and subjected to DSC analysis.
Samples were dialyzed into 20mM potassium phosphate, 300mM sodium
chloride, and 30mM sodium citrate for four days with four buffer changes. Buffer
pH was adjusted to 7.5 by the addition of sodium hydroxide solution. Following
dialysis, serum samples were diluted in dialysis buffer (1 :25) and excess specific
heat readings at temperature ranges from 45°C to 90°C were determined using a
differential scanning calorimeter (MicroCal VP-Capillary DSC; Instrument
software: VPViewer 2000 v.2.0.53). Duplicate runs were completed and average
values for each sample were generated. Total protein concentrations were
determined via BCA and BGG assays and the concentrations determined were
used to normalize DSC readings.

DSC-Human Serum Profiles
For generation of human serum thermogram profiles, dialysis buffer was
formulated as before and 3 ml of pooled human serum was dialyzed for a period
of four days at 4C. Following dialysis, serum was filtered through a 0.45 micron
filter and 99 ~I aliquots were made for spiking with GRFT, GRFT1ec-, or PBS.
Dialysis buffer, to serve as a reference, was sterile filtered and stored at 4°C.
GRFT and GRFT1ec- dilutions in PBS were prepared ranging from 20,000 nM to
100 nM. Dialyzed serum aliquots were spiked with GRFT, GRFT1ec-, or PBS by
the addition of 1~I of GRFT dilution to the 99 ~I of dialyzed serum. The resulting
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final concentrations ranged from 1nM to 200nM, respectively to cover the ranges
of GRFT concentrations observed in guinea pig serum after subcutaneous
dosing. Spiked serum samples were diluted in dialysis buffer (1 :25) and excess
specific heat readings at temperature ranges from 45°C to 90°C were determined
using a differential scanning calorimeter. As before, BCA and BGG assays were
conducted and total protein concentrations were used to normalize thermogram
readings.
Protease Resistance
GRFT's resistance to proteolytic degradation was evaluated using a
number of proteases of the Kallikrein family known to be present in blood,
seminal fluid and vaginal fluid. Recombinant Kallikrein proteases 3,5,7, 11, 12,
and 13 (R&D Systems) were reconstituted and activated according to
manufacturer recommended activation protocols. In addition to Kallikrein
proteases, MMP-12 (R&D Systems), neutrophil elastase (Sigma), and Trypsin
(R&D) were also chosen for evaluation. All proteases were reconstituted and
activated, if necessary, per manufacturer's instructions.
To approximate both vaginal and seminal fluid environments, vaginal and
seminal simulant fluids were formulated according to Owen and Katz [105-106].
In both vaginal and seminal simulant solutions, BSA was omitted in order to
avoid potential quenching activity by the BSA. Vaginal simulant solution pH was
adjusted by the addition of HCL. Sodium hydroxide solution was used to adjust
the pH of the seminal fluid simulant.
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In addition to seminal and vaginal fluid simulants, assay buffers were
prepared according to the manufacturer's directions to serve as optimal activity
conditions for each protease. For neutrophil elastase, a buffer of 50 mM ACES
buffer pH 7.2 with 50 11M CalMg was used for optimal activity conditions
To test GRFT's proteolytic resistance, 2.5 III of GRFT (5.4 mg/ml) was
combined with 20 III of activated protease and 17.5 III of either optimal activity
buffer, seminal fluid stimulant, or vaginal fluid simulant. After addition of GRFT,
samples were vortexed and split evenly between two Eppendorf tubes and
incubated for either 1 or 6 hours at 3]oC. Ten microliter (10 Ill) aliquots of
protease mixture in optimized assay buffer were analyzed by mass spectrometry
by direct infusion of the mixture into the instrument. Remaining samples for all
proteases were analyzed by either SDS-PAGE or Western blot to assess GRFT
degradation. Degradation was considered positive if there were a loss or
substantial decrease in intensity of the GRFT 12.5 kD protein band or if
deconvoluted mass spectra showed appearance of degradation products.
Hemagglutination
GRFT's hemagglutination activity in other species aside from guinea pig
was analyzed. To test GRFT's hemagglutination activity, human, mouse, and
sheep erythrocytes (Innovative Research) were washed with PBS to remove cell
degradation and lysis products. Cells were spun down at 1000 x g for one minute
and resuspended at a final concentration of 2% in PBS containing 3 giL BSA and
1 giL sodium azide. Serial dilutions of either Phytohemagglutinin (PHA) (positive
control) or GRFT were mixed with an equal volume of erythrocytes in a 96 well
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round bottom plate (total 100 IlUwell) and incubated for 1 hr at room
temperature, followed by overnight at 4°C. Plates were then allowed to dry.
Hemagglutination activity was determined by examination of erythrocyte
aggregation or dissemination in comparison to positive and negative control
wells. Positive hemagglutination activity was indicated by diffuse blood cells
along the bottom of the dried plate, denoting formation of a lattice structure due
to agglutination of multiple erythrocytes. Negative hemagglutination activity was
observed as a single dot on the bottom of the well, indicating no cell crosslinking.
Co-Immunoprecipitation of GRFT from human serum
Indirect co-immunoprecipitation of GRFT binding ligands in human serum
was performed using Dynabeads. Briefly, Dynabeads coated with sheep antirabbit IgG were used to precipitate rabbit anti-GRFT antibodies that were either
incubated with human serum containing GRFT or pre-coated with GRFT.
4.5 ml human serum (Innovative Research) was aliquotted into 15 ml
tubes. 4.5 ml of PBS was added to each flask to dilute serum for easier
magnetic separation. Dynabeads at a concentration of 6.7 x 106 beads/ml were
separated into four- 500 III aliquots. Four test groups were set up for analysis as
outlined below.
For test Group A, serum, PBS, and 500 III Dynabeads were combined and
incubated at 4°C overnight with gentle agitation. For test Group B, 500 III
Dynabeads was allowed pre-bind to 6 Ilg of rabbit anti-GRFT antibodies for one
hour at 3rC. After incubation, beads were placed on a magnetic rack for
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separation and supernatant containing unbound antibodies was removed and
discarded. Beads were then washed twice PBS. After a final magnetic
separation, Dynabeads were resuspended in 500 III of PBS and added to serum
and PBS.
For test Group C, 500 III of Dynabeads were combined with 6 Ilg of rabbit
anti-GRFT antibodies and an excess of GRFT (200 Ilg) for one hour at 37°C. As
before, after incubation, beads were placed on a magnetic rack for separation
and supernatant containing unbound antibodies and GRFT was removed and
discarded. Beads were then washed twice PBS. After a final magnetic
separation, Dynabeads were resuspended in 500 III of PBS and added to serum
and PBS.
Finally, for test Group D, 500 III Dynabeads, 200 Ilg GRFT, and 6 Ilg of
rabbit anti-GRFT antibodies was added to PBS and serum simultaneously to
avoid pre-binding of any of the proteins and antibodies.
All test groups were incubated overnight at 4°C with rotation to facilitate
protein binding. After overnight incubation at 4°C, Dynabeads were separated
from the samples via magnetic separation. Supernatant was removed via pipette
and beads were resuspended in 8 ml PBS for washing. Beads and PBS were
mixed for two minutes by gentle rocking of the test tube. After thorough mixing,
tubes were placed on a magnetic rack for separation and the supernatant was
removed and discarded. The washing process was repeated with an additional 8
ml of PBS and samples were prepared for protein elution.
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Elution of the isolated rabbit anti-GRFT antibody, GRFT, and GRFTprotein complexes were performed via pH shift to denature the bead bound
antibodies. Briefly, 75 III of 0.1 M citrate buffer of a pH of 2.7 was added to
immobilized beads. Samples were gently mixed via pipetting for two minutes.
Following mixing, tubes were placed on a magnetic strip and the supernatant
containing Ig, GRFT, and protein complexes was transferred to an Eppendorf
tube. The elution process was repeated with an additional 75 III of citrate buffer
and samples from both elutions were combined. GRFT and protein presence in
eluates was examined via SDS-PAGE and Western blot. Eluates were also
subjected to mass spectrometry for analysis and identification of any proteins
eluted from the co-immunoprecipitation samples.
For identification by mass spectrometry, protein samples were dried by
speedvac and dissolved with 8 M urea in 50 mM NH 4 HC03 (pH 8). Samples were
then reduced with dithiothreitol, alkylated with iodoacetamide, diluted with 50 mM
NH 4 HC03 and digested with trypsin at 3rC overnight. Trypsin digests were
desalted with C 18 spin column (Pierce, Rockford, IL) and concentrated by
speedvac. Concentrated samples were then loaded on to a C 18 Il-Precolumn
Cartridge from Dionex (Sunnyvale, CA) and peptides in the samples were
separated with a packed C 18 capillary column with an acetonitrile and 0.1 %
formic acid gradient by a nanoAcquity LC system. The eluted peptides were
directed to a LTO Orbitrap XL mass spectrometer (Thermo Fisher Scientific, San
Jose, CA) via a nanospray source and MS/MS spectra of the peptides were
acquired by data dependent scan with mass resolution of 100,000 and 7,500 in
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MS and MS/MS mode respectively. The database search was performed by
Proteome Discoverer 1.2 from Thermo Fisher Scientific with SEQUEST algorism
and SwissProt database (Feb 8, 2011). Only proteins with minimum of 2
distinguish high confident peptide matches (XCorr score 1.9, 2.3 and 2.6 for
precursor ion charge state 2,3, and 4 respectively) were reported as positive
identifications.
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RESULTS

DSC- Guinea Pig Serum Thermograms
Serum from guinea pigs treated with GRFT and GRFT1ec- displayed a
substantial shift in excess specific heat capacity versus control animals treated
with PBS (Figure 3.1). Group member thermograms were averaged and excess
specific heat capacity was plotted against temperature. Groups 2a and 3a (24
hours after last treatment) displayed the greatest increase in excess specific heat
capacity, with Groups 2b and 3b (120 hours after last treatment) continuing to
display a discernable increase in excess specific heat capacity. GRFT or
GRFT1ec- treated groups also displayed a nominal increase in the temperature at
which the serum thermograms peaked. However, comparisons between time
points demonstrated that as GRFT or GRFT1ec- concentrations decreased in
serum, average serum thermograms began to approach values obtained from
PBS treated control groups.

DSC- GRFT and GRFT1ec- spiked human serum
Human sera spiked with varying concentrations of GRFT did not display a
substantial shift in thermograms versus PBS-spiked control serum. (Figure 3.2).
Furthermore, at all concentrations tested, with the exception of 100 nM GRFT,
GRFT spiked serum showed a minor decrease in excess specific heat capacity in
the first peak of the serum thermogram.
Human sera spiked with varying concentrations of GRFT1ec- also did not
display a general shift in serum thermograms profiles versus PBS-spiked control
serum. (Figure 3.3). However, at 1nM concentrations of GRFT
54

1ec

-,

there appears

to be a greater magnitude of decrease in excess specific heat capacity as
compared to other molarities. Nonetheless, visual comparisons between GRFT
and GRFT1ec- spiked groups did not display any characteristic differences in
serum thermogram profiles between the groups.
Protease Resistance
GRFT was resistant to all proteases tested, under all assay conditions,
and at all time points tested. Six-hour incubations of GRFT with various kallikrein
proteases and MMP-12 in optimized protease activity buffers was visualized
using SOS-PAGE analysis with Coomassie blue staining (Image 3.1).
Comparisons between the GRFT standard and the GRFT present in protease
incubated samples does not reveal any substantial degradation or decrease in
intensity of the GRFT band. These results were also observed samples
incubated in vaginal and seminal simulant fluids at both 1 hour and 6 hours.
GRFT resistance to all proteases tested was also confirmed via mass
spectrometry. Selected deconvoluted spectra from GRFT incubated with
proteases are shown in Figure 3.4. A GRFT -only control was used to determine
typical fragmentation. Analysis of deconvoluted spectra from samples incubated
in optimized protease activity buffers did not reveal substantial GRFT
degradation at any time point tested.
Hemagglutination
GRFT's hemagglutination activity in sheep, human, and mouse blood was
analyzed (Image 3.2). Visual inspection of wells containing suspended blood
samples, PHA, PBS, and GRFT were conducted. As expected, PBS did not
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exhibit any hemagglutination activity in any species. PHA, a lectin with known
hemagglutination activity, demonstrated activity in the 0.5 mg/ml to 10 Ilg/ml
range (0.3IlM to 78.1 nM range). Comparisons between wells demonstrated that
GRFT did not possess hemagglutination activity in human, sheep, or mouse
samples (mouse samples not shown) at any of the GRFT concentrations tested.
Co-Immunoprecipitation of GRFT from Human Serum
Co-Immunoprecipitation of GRFT/serum complexes was moderately
successful. GRFT was captured from serum using the method described above,
but at substantially less quantities than expected. Western blot analysis of coimmunoprecipitation eluates demonstrated that groups C and 0 recovered
detectable amounts of GRFT from serum incubations. Mass spectrometric
analysis of the eluates revealed a number of proteins were retrieved from the
serum by the various groups (Figure 3.5). After eliminating kertinocyte related
proteins and proteins retrieved by non-GRFT bound beads, a number of
candidate binding partners were identified.
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Figure 3.1. Mean serum thermograms of guinea pig groups treated with PBS,
GRFT, or GRFT1ec-. Excess specific heat capacity of guinea pig serum averaged
amongst groups was plotted against temperature to generate serum
thermograms. As compared against control groups 1a and 1b, GRFT and
GRFT1ec- treated animals displayed an overall increase in excess specific heat
capacity as well as a small increase in temperature peak. Intra-group
comparisons of GRFT and GRFT1ec- treatment groups show a decrease in
specific heat and temperature at 120 hours post treatments vs. 24 hours post
treatments.
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Human Serum Thermogram (GRFT-Spiked)
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Figure 3.2. Thermogram of human serum spiked with varying concentrations of
GRFT. Human serum was spiked with varying concentrations of GRFT and
excess specific heat capacity was plotted against temperature to generate
thermograms. Spiking of serum with GRFT at the concentrations listed above
did not result in substantial changes in serum thermograms. Only one spiking
group, 100nM GRFT, showed a nominal increase in excess specific heat
capacity versus serum spiked with PBS.
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Figure 3.3. Thermogram of human serum spiked with varying concentrations of
GRFT1ec-. Human serum was spiked with varying concentrations of GRFT1ec- and
excess specific heat capacity was plotted against temperature to generate
thermograms. Spiking of serum with GRFT at the concentrations listed above
did not result in an increase in excess specific heat. However, at 1nM
concentrations of GRFT1ec-, serum samples appeared to have a decrease in
excess specific heat capacity.
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Image 3.1. SOS-PAGE gel of six-hour incubations of GRFT with various
proteases. GRFT was exposed to different proteases and incubated for 6 hours
in optimized protease activity buffers. GRFT did not display any significant
degradation from any of the proteases tested.
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Figure 3.4. Selected mass spectra of GRFT digestions. Six-hour incubations of
GRFT with proteases in optimized activity buffers were analyzed by mass
spectrometry. Deconvoluted mass spectrometry analysis of directly infused
confirmed that GRFT did not experience any significant degradation from the
proteases tested.
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Image 3.2. Hemagglutination activity of GRFT on human and sheep
erythrocytes. Hemagglutination activity of GRFT on human and sheep
erythrocytes was analyzed. Phytohemagglutinin (PHA) was used as a positive
control. PBS was used as a negative control. Comparison of wells shows that
GRFT did not display Hemagglutination activity on either sheep or human blood
in any of the ranges tested.
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Unique Human Co-IP Products
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Figure 3.5. Human serum proteins acquired via GRFT co-immunoprecipitation
using Dynabeads. Co-Immunoprecipitation products for groups A, B, C, and 0
were analyzed. Control Groups A and B products were non-specific binding
products of Dynabeads or polyclonal rabbit anti-GRFT antibodies. The table
above represents the final products of Groups C and 0, after excluding nonspecific protein binding and keratinocyte related proteins.
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CONCLUSIONS AND FUTURE DIRECTIONS

esc
Systemic administration of GRFT may result in changes in serum
thermograms that are not observable in GRFT-spiked serum. Given the changes
observed in guinea pig serum of treated animals versus controls, GRFT
administration may be having some impact on either the serum interactome or
inducing changes in major serum protein components. Furthermore, in contrast
to serum thermogram changes observed in GRFT and GRFT

1ec

-

treated guinea

pigs, spiking of human serum with GRFT and GRFT1ec- did not result in a
substantial shift in serum thermogram profiles. As such, it is currently unknown
whether the difference in thermogram shift results is a product of inter-species
differences, changes in serum proteins, or changes in protein interactions.
Further experiments are required in order to determine GRFT's impacts upon
serum thermograms as well as to identify potential endogenous binding partners.
Proteolytic Resistance
GRFT has displayed a strong proteolytic resistance to all proteases
tested. Accordingly, GRFT continues to be a strong candidate for systemic
administration given that it remains active when exposed to diverse proteases
that it may encounter both in vaginal tissues as well as in systemic circulation.
Co-immunoprecipitation
GRFT is immunoprecipitated from human serum by use of anti-GRFT
antibodies. Additionally, potential serum binding partners of GRFT were able to
be isolated and identified by co-immunoprecipitation and mass spectrometry.
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However, refinement of the immunoprecipitation protocols is needed to increase
the efficiency of the GRFT-protein complex extractions. First, experiments are
needed to determine whether the GRFT precipitated from serum is free GRFT
that isn't bound to any serum partner. Further, there also exists the possibility
that the serum proteins to which GRFT may bind are of such a low quantity that
efficient detection and identification will require large amounts of serum to be
precipitated. Accordingly optimization of precipitation protocols will be essential
in definitively establishing identities of potential serum binding partners for GRFT.
Additionally, the difference in Co-IP products between GRFT pre-bound
and GRFT non pre-bound elutions after elimination of non-specific binding
products raises the possibility of stearic inaccessibility of GRFT once bound to
certain proteins. Given that the GRFT pre-bound to beads yielded a greater
number of proteins, it would appear that this method would likely provide the
greatest source of binding information. However, we cannot exclude the
possibility that binding of GRFT to a protein hides the epitopes recognized by the
antibodies. Interestingly, the presence of apoliprotein E in both samples may
provide an indication of why GRFT administration resulted in less weight gain
during treatment than PBS treated controls. Given apoliprotein E's role in lipid
catabolism, there may be some unseen disruption in this process. However, we
cannot rule out the possibility of some inflammatory reaction to the presence of
the protein in systemic circulation as a greater contributing factor to the weight
difference observations.
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Future Directions
In the future, we shall conduct guinea pig and human serum spiking
experiments using a greater range of concentrations of GRFT to determine
whether thermogram shifts are a result of endogenous serum protein binding, or
a currently unrecognized biological toxicity. Additionally, using Differential
Scanning Calorimetry, we shall investigate the thermodynamic impact of
systemic GRFT treatment, as well as GRFT and GRFT1ec- spiking, upon serum to
characterize GRFT's impact upon the serum interactome. Further, using 2D gel
electrophoresis and commercially available multiplex immunoassays, we intend
to examine changes in serum proteins, cytokines, chemokines and other
biomarkers resulting from GRFT treatment in rats and mice to determine whether
any observable changes are a result of drug presence or a result of endogenous
protein binding.
Additionally, using co-immunoprecipitation of GRFT in Human serum, we
shall attempt to catalogue potential endogenous binding partners of GRFT.
Using mass spectrometry, we shall identify endogenous binding partners as well
as determine the effects that binding may have upon endogenous serum
interactions.
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CHAPTER 4

ANALYSIS OF GRFT RESISTANT HIV STRAIN AND GENERATION OF HIVENV PSEUDOVIRUS TO DETERMINE GRFT NEUTRALIZATION CAPCACITY

INTRODUCTION
The ability of antiviral and antimicrobial agents to neutralize HIV has been
measured through the use of pseudovirus technology [93, 107-108]. Providing
many advantages over handling of live HIV particles, Env pseudovirus
technology allows for greater reproducibility and precision, as well as allows for
the analysis of relative infectivity of individual envelope isolates.
Briefly, 293FT cells, derived from human embryonic kidneys and
transformed with the SV40 T antigen, are used to produce high titer lentiviruses
due to their high transfectability. Conventionally, two plasm ids are used for
transfection and pseudovirus production. The first plasmid possesses genes
encoding the viral backbone and Tat-genes, but lacking the env gene of HIV.
The second plasmid possesses the desired env genes. Co-transfection of the
293FT cells with both plasm ids results in the production of pseudovirions that
possess envelopes capable of infecting target cells expressing CD4 and the
CXCR4 and CCR5 co-receptors, but unable to replicate.
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Once produced, pseudovirus particle titers are determined through the
usage of TZM-bl cells. TZM-bl cells are HeLa cells which have been engineered
to express CD4 and CCR5 in addition to expressing their already present CXCR4
receptors[109]. As such, they are permissive to infection by a wide variety of HIV
strains, including HIV, SIV, and Env-pseudotyped viruses. In addition to
presenting necessary receptors for infection, this cell line has also been further
engineered to contain Tat-responsive reporter genes for luciferase and Bgalactosidase [110].
Upon successful infection of TZM-bl cells by env-pseudotyped particles,
the Tat gene contained on the env-minus plasmid is delivered into the TZM-bl
cells, inducing an increase in the production of luciferase. Relative infectivity, as
well as neutralization capacity of various drugs, can thus be measured as a
function of luciferase gene expression in the presence of luciferase substrate. As
such, it is a useful mechanism for examining the effectiveness of agents which
can prevent viral infection since successful infection by the pseudovirus particle
will result in an increase in chemiluminescence.
As such, studies into the ability of GRFT to prevent TZM-bl cell infection
with Env-pseudotyped particles can provide an important tool in examining the
gp120 spike of HIV, a necessary structure for successful infection. Via site
directed mutagenesis, changes to the env encoding genes can be made that
alter potential N-linked Glycosylation Sites (NLGS). Given antiviral activity GRFT
demonstrates through its binding to the high-mannose glycans attached to these
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NLGS, the impact of NLGS changes on GRFT's effectiveness can be evaluated
and quantitated.
In this chapter we will examine the glycosylation states of Du156.12, an
HIV isolate that is susceptible to neutralization by GRFT, as well as Du156.R18,
an HIV isolate which has acquired resistance to GRFT neutralization. Finally, we
will describe the production and optimization of HIV env-pseudoviruses that will
be used to measure a GRFT neutralization capacity in future experiments
wherein antibody responses to GRFT are elicited.
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MATERIALS AND METHODS

Gene Sequencing of Du156.12 and Du156.R18
Plasmids of HIV env were supplied by Dr. Montefiori of Duke University.
Plasmids containing gp120 and gp41 sequences (cloned into pcDNA3.1) from
strains Du156.12 and Du156.R18 (a GRFT-resistant strain of HIV) were provided
for analysis and comparison. Competent dh5-alpha bacteria were transformed
with the appropriate plasmid containing either Du156.12 or Du156.R18 sequence
strands.

After transformation, transformed bacterial colonies were isolated by

streaking on a plate containing ampicillin for selection. After 12 hours of growth,
four (4) colonies from each strain were selected and grown in LB broth overnight
at 37C with vigorous shaking. Du156.12 and Du156.R18 env plasm ids were
then extracted from bacterial cultures via Miniprep (Quiagen) kit per the
manufacturer's instructions.
Aliquots of plasmid preparations containing forward and reverse primers
for gp120 and gp41 were sent for sequencing. Eleven (11) primers were used
for sequence generation (Table 4.1). Sequencing results were aligned and
consensus sequences were generated on Sequencher 4.8 software.
Pseudovirus generation
Pseudovirus particles for HIV-env neutralization assays were generated
using modified methods previously described [93]. Briefly, 293 FT cells were
cultured for transfection with HIV-env containing plasm ids. Eighteen (18) hours
before transfection, cells were plated at a density of 6x1 06 . On the day of
transfection, cells were visually inspected and were 50% confluent. Transfection
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media was prepared by combining120 III of Fugene HO, 12 Ilg of endotoxin free
Ou156.12 plasmid, and 48 Ilg of pSG3 plasmid in 480 III of OMEM. After mixing,
the media was allowed to react at room temperature for 30 minutes. At the end
of 30 minutes, the reaction mixture was added in a drop-wise manner to plated
293FT cells with gentle swirling of the cell culture plate.
Plates of transfected cells were allowed to incubate at 3]DC for a period of
5 hours. At the end of 5 hours, transfection media was removed and replaced
with fresh media. Transfected cells were placed in a 32°C incubator with 5% C02
and allowed to incubate for a period of 72 hours. At the end of 72 hours, media
containing pseudovirus particles was collected, centrifuged at 1000 x g for 15
minutes, and aliquotted for pseudovirus titration.
Pseudovirus Titration
Titration of media containing pseudovirus particles was conducted via
titration in TZM-bl cells to probe for changes luciferase expression due to
successful infection with pseudovirus particles containing the luciferase promoter
gene. Briefly, serial dilutions of pseudovirus stock ranging from undiluted to a
dilution of 1:78125 were placed into 96-well white tissue culture plates, by
addition of pseudovirus stocks to wells containing 100 III of media (OMEM with
10% FBS - no phenol red) in all wells. 100 III of TZM-bl cells at a density of

100,000 cells/ml in media (OMEM with 10% FBS- no phenol red) were added to
all wells and incubated at 3]DC for 72 hours. Cells only wells, containing no
pseudovirus stock were used as background-Iuciferase production controls. At
the end of 72 hours, culture media was removed and the cells were gently
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washed by the addition of 200
lysed by addition of 50

~I

~I

of PBS. PBS was removed and cells were

of room temperature lysis buffer and 30 minutes of

vigorous shaking. Luciferase detection reagent was prepared by dissolving the
luciferase assay substrate in 10 mL of luciferase assay buffer. After cells were
lysed, luciferase activity was measured by the addition of 100

~I

of luciferase

detection reagent to each sample well. Chemiluminescence was read
immediately.
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RESULTS

Gene Sequencing of Du156.12 and Du156.R18
Sequencing of Du156.12 and Du156.r18 revealed a number of
glycosylation changes in the Du 156.r18 gp120 sequence that resulted in four
glycosylation site deletions and one glycosylation site addition (Figure 4.1). Two
glycosylation site deletions, one at the beginning of the V3 domain and one
between the V4 and V5 domains were the result of base changes which resulted
in the Asn-X-SerfThr sequon being eliminated. Namely, the sequon deletion at
the beginning of the V3 domain of Du 156. R 18 was the result of an Asparagine
being substituted with a Serine residue. The sequon deleted between V4 and V5
was the result of a Threonine being substituted with an Isoleucine residue in the
N-X-T sequon.
However, residue substitution was not the only mechanism by which
Du156.R18 modified its NLGS. Two of the four potential N-linked glycosylation
site deletions were the result of a 30 amino acid deletion in the V1/V2 loop, which
resulted in a shortening of the V1N2 loop by 10 residues. In contrast to the
glycosylation site deletions, there was the addition of one glycosylation site at
residues 341-343 by the substitution of Threonine for Alanine, which resulted in
the creation of aN-linked glycosylation site sequon.
Pseudovirus Generation and Titration
Titration of Pseudovirus particle containing media in TZM-bl cells revealed
a successful creation of infective Du156.12 pseudoparticles (Figure 4.2).
Chemiluminescence, expressed in Relative Luminescence Units (RLU) was
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plotted against virus stock dilution. Titre results showed that undiluted virus
stocks resulted in an almost 6 fold increase in luciferase expression in TZM-bl
cells, producing an average RLU of 20448. Furthermore, this increased
expression was observable at even the lowest viral concentrations tested
(1 :78125 dilution of virus stocks). Background TZM-blluciferase activity was
determined to be 3600.
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Sequence Name

Sequence 51 to 3 1

GRFTr1

ATGTGTAAGGTGGCGGG

GRFTr2

CACAAGCCTGTCCAAAGG

GRFTr3

TTGAACCACCCTCAGGAG
...••.................................

I·

GRFTr4

TGCTGCTCCCAAGAACC

GRFTr5

GGGTCTGAAACGACAAAGG

Gp120f

TAATGTGTAAGGTGGCGGG

chimerolap1

AGGCTTGTGTTATGGTTGAGG

chimeraolap2

CATAACACAAGCCTGTCCAA

gp120r

ACAGCTCCTAGTCCCACTG

Du156f

CGAAGCACTCCTCCAAGTAA

Du156r

GGGTCTGAAACGACAAAGG

Table 4.1. Primers used for Du156 sequencing. The above forward and reverse
primers were used to generate consensus sequences of plasmids containing
HIV-env Du156.12 and Du156.R18.
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Ref: Du156 .12
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II
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I
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Ref: Du156.R18

o

V3

300

400

460

450

Figure 4.1. Potential N-linked glycosylation sites (NLGS) of gp120 of Du156.12
and Du156.R18. Sequencing analysis of Du156 .12 and Du156.R18 revealed a
number of NLGS changes. Sequons of Asn-X-Ser and Asn-X-Thr, where X ¢Pro
were recorded. Two (2) NLGS were deleted by removal of 10 amino acid
residues (SSATYNNSMN) in the V1/V2 loop of Du156.R18. Du156.R18 also
displayed a deletion of one NLGS in V3, an addition of one NLGS in V4, and a
deletion of one PNGS near residue 400. Total NLGS for Du156.12 totaled 24,
whereas Du156.R18 had a total of 21 NLGS.
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Figure 4.2. Pseudovirus titre of Du.156.12 in TZM-bl cells. Analysis of
pseudovirus production in 293FT cells for GRFT neutralization assays
demonstrated production of infective HIV-env virions. Undiluted samples
displayed an average chemiluminescence reading of 20448 Relative
Luminescence Units (RLU). At a 1:78125 dilution of pseudovirus stocks,
chemiluminescence was still detectible, with an average rating of 11748 RLU.
Cells-only background wells displayed an average RLU of 3600.
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CONCLUSIONS AND FUTURE DIRECTIONS

Gene Sequencing of Du156.12 and Du156.R18
Differences in NLGS between DU156.12 and Du156.R18 may be
responsible for its resistance to GRFT neutralization. With less potential highmannose glycans present on gp120, GRFT's ability to impede infection of cells
may be reduced. However, it is important to note that two of the glycan deletions
were a result of a 10 residue deletion in the V1N2 region of gp120, thus
shortening the V1N2 loop while simultaneously eliminated two NLGS. Previous
studies have shown that a shortened V1N2 loop may result in increased
infectivity of viral isolates [56-57]. Accordingly, there may be some synergistic
effect between the loss of NLGS and shortening of the V1 N2 loops which
promotes viral evasion of GRFT binding while simultaneously allowing closer
interaction with cellular receptors necessary for viral infection.
Pseudovirus Generation and Titration
Pseudovirus particles from the Du156.12 strain of HIV will be a useful
control for examining GRFT's potential neutralization capacity in other
experiments, including long term animal dosing. Accordingly, Du156.12 envpseudoviruses will be a useful starting point for the induction of NLGS changes to
observe how GRFT's activity is impacted as NLGS are modified. However,
further optimization of the pseudovirus production protocol is needed in order to
increase RLUs even higher above background to increase overall assay
sensitivity.
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Once optimized, the use of this HIV-1 pseudovirus technology will enable
us to fully evaluate the impact that an antibody response will have upon the
neutralization capacity of GRFT. If continued activity of GRFT is seen in
pseudovirus assays despite an antibody response, this finding would indicate
that GRFT treatment may continued even though an antibody response is
mounted. However, should GRFT become less active after an immune response
is generated, it may indicate that GRFT's usefulness would be limited to short
term courses of therapy.
In the future, it would be prudent determine binding interactions between
GRFT and modified gp120 glycans. As mentioned before, pseudovirus
neutralization assays are powerful tools to assess GRFT's neutralization capacity
versus gp120's possessing modified glycans. Via site-directed mutagenesis,
potential NLGS's could be eliminated and HIV-env mutations should be tested
against GRFT concentrations in pseudovirus neutralization assays. Additionally,
purified gp120-GRFT interactions should be probed using isothermal titration
calorimetry, analytical ultracentifugation, and protein binding assays to explore
affinity and avidity interactions between modified gp120s and GRFT in order to
evaluate the impact that viral NLGS mutation has upon GRFT's inhibitory
capacity.
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CHAPTER 5

OVERALL RESEARCH IMPLICATIONS AND APPLICATIONS

HIV treatment

The totality of the research presented in this thesis supports GRFT's utility
as a new adjunct therapy to assist in combating chronic HIV infection. As we
have demonstrated, GRFT can be maintained in serum at levels far exceeding its
anti-HIV-1 EC 5o . We also showed that GRFT is well tolerated in animals when
dosed subcutaneously, with little impact upon organ systems, CBC counts, and
serum chemistries. While hemagglutination assays did demonstrate
agglutination activity on guinea pig erythrocytes, no such activity was seen in
human erythrocytes. Thus it is questionable whether some of the systemic
effects observed in guinea pigs would occur in humans.
Given the various mechanisms of the various HAART treatment regimens,
GRFT treatment could provide an additional method of interrupting the infection
cycle of HIV as well as extending the useful life of current therapies. By
preventing fusion with cells, GRFT may be useful in reducing infection of
uninfected cells as well as prolonging the usefulness of other anti-HIV therapies
by binding to drug resistant escape mutants when viral loads are pushed to
undetectable levels. This may effectively decrease the speed with which HIV
80

acquires resistance to other HAART drugs by denying drug-resistant escape
mutants an opportunity to establish a foothold in uninfected cells.
Further research into the systemic effects in other species will be
necessary in order to determine whether the tolerability profile observed in
guinea pigs is consistent among species. Additionally, research into how an
antibody response will impact GRFT's systemic profile and activity are
necessary. As a foreign protein capable of generating an immune response,
GRFT will have to maintain activity in the face of an immune response given that
immunosuppressive options used to reduce the body's response to a
proteinacious therapy may not be viable given the nature of HIV infection.
Prophylaxis
GRFT translocation into the vaginal mucosa also supports GRFT's utility
in combating HIV, albeit in a different manner. With GRFT being found present
in vaginal mucosal washes, systemic GRFT treatment provides the opportunity to
have GRFT persistently at one of the major portals of infection- the vaginal
mucosa. Accordingly, GRFT may prove to be a second line protection useful for
serodiscordant partners should longer term GRFT immunotherapy become a
viable pre-exposure prophylaxis modality.
Immunotherapy
As has been demonstrated before, HIV-1 resistance to GRFT and other
lectins has entailed the removal of high mannose glycans via alterations in Nlinked glycosylation sites [4, 7, 111]. Burst therapy, the use of the drug over
short periods of time, may be a way to encourage viral evolution towards the
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removal of epitope obscuring high-mannose glycans. Accordingly, the favorable
short term profile that was observed in guinea pigs suggests that should even
long term treatment with GRFT not be feasible due to potential immune reactions
or unseen toxicties, GRFT may still be a viable tool in combating HIV.

Differential Scanning calorimetry.
Current assays have not demonstrated any toxicities of GRFT.
Accordingly, novel methods to identify potential toxicities are necessary fully
understand the impact of adding GRFT into a living system. DSC thermograms
can be used to measure complex biochemical binding interactions as well as
provide potential information into biocomparability. The use of DSC to evaluate
the impact of GRFT therapy may ultimately provide a screening mechanism by
which to measure potential biological impacts not observable by other methods.

82

REFERENCES
1.
2.

3.

4.

5.

6.
7.
8.

9.
10.

11.
12.

13.

www.UNAIDS.com. retrieved 2/15/2011.
Operskalski, E.A. and A. Kovacs, HIVIHCV Co-infection: Pathogenesis,
Clinical Complications, Treatment, and New Therapeutic Technologies.
Curr HIV/AIDS Rep, 2011. 8(1): p. 12-22.
Bertaux, C., et aL, Entry of hepatitis C virus and human immunodeficiency
virus is selectively inhibited by carbohydrate-binding agents but not by
polyanions. Virology, 2007. 366(1): p. 40-50.
Alexandre, K.B., et aL, Mannose-rich glycosylation patterns on HIV-1
subtype C gp 120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N
and Scytovirin. Virology, 2010.402(1): p. 187-96.
Helle, F., et aL, Role of N-linked glycans in the functions of hepatitis C
virus envelope proteins incorporated into infectious virions. J Virol, 2010.
84(22): p. 11905-15.
Balzarini, J., Targeting the glycans of glycoproteins: a novel paradigm for
antiviral therapy. Nat Rev Microbiol, 2007. 5(8): p. 583-97.
Balzarini, J., Inhibition of HIV entry by carbohydrate-binding proteins.
Antiviral Res, 2006. 71 (2-3): p. 237-47.
O'Keefe, B.R., et aL, Broad-spectrum in vitro activity and in vivo efficacy of
the antiviral protein griffithsin against emerging viruses of the family
Coronaviridae. J Virol, 2010.84(5): p. 2511-21.
Francois, K.O. and J. Balzarini, Potential of carbohydrate-binding agents
as therapeutics against enveloped viruses. Med Res Rev, 2010.
Witvrouw, M., et aI., Resistance of human immunodeficiency virus type 1
to the high-mannose binding agents cyanovirin N and concanavalin A. J
Virol, 2005. 79(12): p. 7777-84.
Zappe, H., M.E. Snell, and M.J. Bossard, PEGylation of cyanovirin-N, an
entry inhibitor of HIV. Adv Drug Deliv Rev, 2008. 60(1): p. 79-87.
Tanaka, H., et aL, Mechanism by which the lectin actinohivin blocks HIV
infection of target cells. Proc Natl Acad Sci USA, 2009. 106(37): p.
15633-8.
Emau, P., et aL, Griffithsin, a potent HIV entry inhibitor, is an excellent
candidate for anti-HI V microbicide. J Med Primatol, 2007. 36(4-5): p. 24453.

83

14.

15.
16.

17.
18.
19.
20.

21.
22.
23.
24.
25.
26.

27.

28.
29.
30.
31.

Mori, T., et aI., Isolation and characterization of griffithsin, a novel HIVinactivating protein, from the red alga Griffithsia sp. J Bioi Chem, 2005.
280(10): p. 9345-53.
Varki, A., et. aI., Essentials of Glycobiology, 2nd Ed., Cold Spring Harbor,
NY., Cold Spring Harbor Press, 2009.
Bosques, C.J., et aI., Effects of glycosylation on peptide conformation: a
synergistic experimental and computational study. J Am Chem Soc, 2004.
126(27): p. 8421-5.
Vigerust, D.J. and V.L. Shepherd, Virus glycosylation: role in virulence and
immune interactions. Trends Microbiol, 2007. 15(5): p. 211-8.
Voet, D., et aI., Fundamentals of Biochemistry, 3 rd Ed., Hoboken, NJ:
Wiley Press, 2008.
Alberts, B., et. aI., Molecular Biology of the Cell, 5th Ed., New York, NY,
Garland Science, 2008.
Doores, K.J., et aI., Envelope glycans of immunodeficiency virions are
almost entirely oligomannose antigens. Proc Natl Acad Sci USA, 2010.
107(31): p. 13800-5.
Douek, D.C., M. Roederer, and R.A. Koup, Emerging concepts in the
immunopathogenesis of AIDS. Annu Rev Med, 2009. 60: p. 471-84.
Swanson, C.M. and M.H. Malim, SnapShot: HIV-1 proteins. Cell, 2008.
133(4): p. 742, 742 e1.
Chan, D.C., et aI., Core structure of gp41 from the HIV envelope
glycoprotein. Cell, 1997. 89(2): p. 263-73.
McDougal, J.S., D.R. Klatzmann, and P.J. Maddon, CD4-gp120
interactions. Curr Opin Immunol, 1991.3(4): p. 552-8.
Choe, H., et aI., The beta-chemokine receptors CCR3 and CCR5 facilitate
infection by primary HIV-1 isolates. Cell, 1996. 85(7): p. 1135-48.
Bjorndal, A, et aI., Coreceptor usage of primary human immunodeficiency
virus type 1 isolates varies according to biological phenotype. J Virol,
1997. 71 (1 0): p. 7478-87.
Berger, E.A, P.M. Murphy, and J.M. Farber, Chemokine receptors as HIV1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev
Immunol, 1999.17: p. 657-700.
Dalgleish, AG., et aI., The CD4 (T4) antigen is an essential component of
the receptor for the AIDS retrovirus. Nature, 1984.312(5996): p. 763-7.
Sattentau, Q.J. and R.A. Weiss, The CD4 antigen: physiological ligand
and HIV receptor. Cell, 1988.52(5): p. 631-3.
Myszka, D.G., et aI., Energetics of the HIV gp120-CD4 binding reaction.
Proc Natl Acad Sci USA, 2000. 97(16): p. 9026-31.
Cormier, E.G. and T. Dragic, The crown and stem of the V3100p play
distinct roles in human immunodeficiency virus type 1 envelope
glycoprotein interactions with the CCR5 coreceptor. J Virol, 2002. 76(17):
p.8953-7.

84

32.

33.

34.
35.
36.

37.
38.

39.
40.
41.
42.
43.

44.
45.

46.

47.

Suphaphiphat, P., M. Essex, and T.H. Lee, Mutations in the V3 stem
versus the V3 crown and C4 region have different effects on the binding
and fusion steps of human immunodeficiency virus type 1 gp 120
interaction with the CCR5 coreceptor. Virology, 2007. 360(1): p. 182-90.
Briz, V., E. Poveda, and V. Soriano, HIV entry inhibitors: mechanisms of
action and resistance pathways. J Antimicrob Chemother, 2006. 57(4): p.
619-27.
Weiss, C.D., HIV-1 gp41: mediator of fusion and targetfor inhibition. AIDS
Rev, 2003.5(4): p. 214-21.
Poveda, E., V. Briz, and V. Soriano, Enfuvirtide, the first fusion inhibitor to
treat HIV infection. AIDS Rev, 2005. 7(3): p. 139-47.
Nawaz, F., et aL, The genotype of early-transmitting HIV gp120s promotes
alphabeta-reactivity, revealing alphabetaCD4+ T cells as key targets in
mucosaltransmission. PLoS Pathog, 2011. 7(2): p. e1001301.
Li, Q., et aL, Peak SIV replication in resting memory CD4+ T cells depletes
gut lamina propria CD4+ T cells. Nature, 2005. 434(7037): p. 1148-52.
Zhang, Z.Q., et aL, Roles of substrate availability and infection of resting
and activated CD4+ T cells in transmission and acute simian
immunodeficiency virus infection. Proc Natl Acad Sci USA, 2004.
101(15): p. 5640-5.
Zhang, Z., et aL, Sexual transmission and propagation of SIV and HIV in
resting and activated CD4+ T cells. Science, 1999.286(5443): p. 1353-7.
Haase, A.T., Perils at mucosal front lines for HIV and SIV and their hosts.
Nat Rev Immunol, 2005. 5(10): p. 783-92.
Shacklett, B.L., et aI., Mucosal T-cell responses to HIV: responding at the
front lines. J Intern Med, 2009. 265(1): p. 58-66.
O'Connor, D.M., A tissue basis for colposcopic findings. Obstet Gynecol
Clin North Am, 2008. 35(4): p. 565-82; viii.
Pudney, J., A.J. Quayle, and D.J. Anderson, Immunological
microenvironments in the human vagina and cervix: mediators of cellular
immunity are concentrated in the cervical transformation zone. Bioi
Reprod, 2005. 73(6): p. 1253-63.
Miller, C.J. and R.J. Shattock, Target cells in vaginal HIV transmission.
Microbes Infect, 2003. 5(1): p. 59-67.
Grivel, J.C., R.J. Shattock, and L.B. Margolis, Selective transmission of R5
HIV-1 variants: where is the gatekeeper? J Transl Med, 2011. 9 Suppl 1:
p. S6.
Chenine, A.L., et aI., Relative transmissibility of an R5 clade C simianhuman immunodeficiency virus across different mucosae in macaques
parallels the relative risks of sexual HIV-1 transmission in humans via
different routes. J Infect Dis, 2010. 201 (8): p. 1155-63.
Olsson, J., et aL, Human immunodeficiency virus type 1 infection is
associated with significant mucosal inflammation characterized by
increased expression of CCR5, CXCR4, and beta-chemokines. J Infect
Dis, 2000. 182(6): p. 1625-35.

85

48.

49.

50.

51.
52.
53.

54.

55.

56.

57.

58.

59.
60.

61.
62.

63.

Nazli, A., et aL, Exposure to HIV-1 directly impairs mucosal epithelial
barrier integrity allowing microbial translocation. PLoS Pathog, 2010.6(4):
p. e1000852.
Poles, M.A., et aL, A preponderance of CCR5(+) CXCR4(+} mononuclear
cells enhances gastrointestinal mucosal susceptibility to human
immunodeficiency virus type 1 infection. J Virol, 2001. 75(18): p. 8390-9.
Bomsel, M., Transcytosis of infectious human immunodeficiency virus
across a tight human epithelial cell line barrier. Nat Med, 1997.3(1): p. 42-

7.
Shen, R., et aL, Dendritic cells transmit HIV-1 through human small
intestinal mucosa. J Leukoc Bioi, 2010.87(4): p. 663-70.
McCoombe, S.G. and R.V. Short, Potential HIV-1 target cells in the human
penis. AIDS, 2006. 20(11): p. 1491-5.
Patterson, B.K., et aL, Susceptibility to human immunodeficiency virus-1
infection of human foreskin and cervical tissue grown in explant culture.
Am J Pathol, 2002. 161 (3): p. 867-73.
Leonard, C.K., et aL, Assignment of intra chain disulfide bonds and
characterization of potential glycosylation sites of the type 1 recombinant
human immunodeficiency virus envelope glycoprotein (gp120) expressed
in Chinese hamster ovary cells. J Bioi Chem, 1990. 265(18): p. 10373-82.
Auwerx, J., et aL, Glycan deletions in the HIV-1 gp120 V1N2 domain
compromise viral infectivity, sensitize the mutant virus strains to
carbohydrate-binding agents and represent a specific target for
therapeutic intervention. Virology, 2008. 382(1): p. 10-9.
Liu, Y., et al., Env length and N-linked glycosylation following transmission
of human immunodeficiency virus Type 1 subtype B viruses. Virology,
2008.374(2): p. 229-33.
Zhang, H., et aL, Restricted genetic diversity of HIV-1 subtype C envelope
glycoprotein from perinatally infected Zambian infants. PLoS One, 2010.
5(2): p. e9294.
Life expectancy of individuals on combination antiretroviral therapy in
high-income countries: a collaborative analysis of 14 cohort studies.
Lancet, 2008. 372(9635): p. 293-9.
Alexaki, A., Y. Liu, and B. Wigdahl, Cellular reservoirs of HIV-1 and their
role in viral persistence. Curr HIV Res, 2008. 6(5): p. 388-400.
Belmonte, L., et aL, Reservoirs of HIV replication after successful
combined antiretroviral treatment. Curr Med Chem, 2003. 10(4): p. 30312.
McNamara, L.A. and K.L. Collins, Hematopoietic stem/precursor cells as
HIV reservoirs. Curr Opin HIV AIDS, 2011. 6(1): p. 43-8.
Shen, L. and R.F. Siliciano, Viral reservoirs, residual viremia, and the
potential of highly active antiretroviral therapy to eradicate HIV infection. J
Allergy Clin Immunol, 2008.122(1): p. 22-8.
Mavigner, M., et aL, HIV-1 residual viremia correlates with persistent T-cell
activation in poor immunological responders to combination antiretroviral
therapy. PLoS One, 2009. 4(10): p. e7658.
86

64.

65.
66.
67.

68.
69.

70.

71.
72.

73.
74.
75.

76.

77.

78.

79.

Watson, C., et aL, The CCR5 receptor-based mechanism of action of
873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol
Pharmacol, 2005. 67(4): p. 1268-82.
Kitchen, C.M., et aL, Enfuvirtide antiretroviral therapy in HIV-1 infection.
Ther Clin Risk Manag, 2008. 4(2): p. 433-9.
Fletcher, C.V., Enfuvirtide, a new drug for HIV infection. Lancet, 2003.
361(9369): p. 1577-8.
Jamjian, M.C. and I.A. McNicholl, Enfuvirtide: first fusion inhibitor for
treatment of HIV infection. Am J Health Syst Pharm, 2004. 61 (12): p.
1242-7.
Robertson, D., US FDA approves new class of HIV therapeutics. Nat
Biotechnol, 2003. 21 (5): p. 470-1.
Dorr, P., et aL, Maraviroc (UK-427,857), a potent, orally bioavailable, and
selective small-molecule inhibitor of chemokine receptor CCR5 with
broad-spectrum anti-human immunodeficiency virus type 1 activity.
Antimicrob Agents Chemother, 2005. 49(11): p. 4721-32.
Symons, J., et aL, Maraviroc is able to inhibit dual-R5 viruses in a
dual/mixed HIV-1-infected patient. J Antimicrob Chemother, 2011. 66(4):
p.890-5.
Soriano, V., et aL, Optimal use of maraviroc in clinical practice. AIDS,
2008.22(17): p. 2231-40.
Castonguay, L.A., et aL, Binding of 2-aryl-4-(piperidin-1-yl)butanamines
and 1, 3, 4-trisubstituted pyrrolidines to human CCR5: a molecular
modeling-guided mutagenesis study of the binding pocket. Biochemistry,
2003.42(6): p. 1544-50.
Kuritzkes, D.R., HIV-1 entry inhibitors: an overview. Curr Opin HIV AIDS,
2009. 4(2): p. 82-7.
Dimitrov, A., Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection.
Curr Opin Investig Drugs, 2007. 8(8): p. 653-61.
Bruno, C.J. and J.M. Jacobson, Ibalizumab: an anti-CD4 monoe/onal
antibody for the treatment of HIV-1 infection. J Antimicrob Chemother,
2010. 65(9): p. 1839-41.
Song, R., et aL, Epitope mapping of ibalizumab, a humanized anti-CD4
monoe/onal antibody with anti-HIV-1 activity in infected patients. J Virol,
2010.84(14): p. 6935-42.
Jacobson, J.M., et aL, Safety, pharmacokinetics, and antiretroviral activity
of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4
monoclonal antibody, in human immunodeficiency virus type 1-infected
adults. Antimicrob Agents Chemother, 2009. 53(2): p. 450-7.
Kuritzkes, D.A., et aL, Antiretroviral activity of the anti-CD4 monoe/onal
antibody TNX-355 in patients infected with HIV type 1. J Infect Dis, 2004.
189(2): p. 286-91.
Chiba, H., et aL, Actinohivin, a novel anti-human immunodeficiency virus
protein from an actinomycete, inhibits viral entry to cells by binding highmannose type sugar chains of gp120. Biochem Biophys Res Commun,
2004.316(1): p. 203-10.
87

80.

Bewley, C.A. and S. Otero-Quintero, The potent anti-HIV protein
cyanovirin-N contains two novel carbohydrate binding sites that selectively
bind to Man(8) 0103 and Man(9) with nanomolar affinity: implications for
binding to the HIVenvelope protein gp120. J Am Chem Soc, 2001.

81.

123(17): p. 3892-902.
Moulaei, T., et aL, Monomerization of viral entry inhibitor griffithsin
elucidates the relationship between multivalent binding to carbohydrates
and anti-HI V activity. Structure, 2010.18(9): p. 1104-15.

82.
83.
84.
85.

Abbas, A., et aL, Cellular and Molecular immunology, Philadelphia, PA:
Elsevier Press, 2010.
Abud-Mendoza, C. and R. Gonzalez-Amaro, Rituximab in systemic lupus
erythematosus. Lupus, 2010. 19(5): p. 658.
Kopp, M.V., Omalizumab: Anti-lgE Therapy in Allergy. Curr Allergy
Asthma Rep, 2011. 11 (2): p. 101-6.
Cox, L., et aL, American Academy of Allergy, Asthma &
Immunology/American College of Allergy, Asthma and Immunology Joint
Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin

Immunol, 2007.120(6): p. 1373-7.
86.

Rituximab (Rituxan) for rheumatoid arthritis. Med Lett Drugs Ther, 2006.

87.

48(1233): p. 34-5.
Garman, R.D., K. Munroe, and S.M. Richards, Methotrexate reduces
antibody responses to recombinant human alpha-galactosidase A therapy
in a mouse model of Fabry disease. Clin Exp Immunol, 2004. 137(3): p.

88.

89.

90.

91.

92.

93.

94.

496-502.
Ziolkowska, N.E., et aL, Crystallographic, thermodynamic, and molecular
modeling studies of the mode of binding of oligosaccharides to the potent
antiviral protein griffithsin. Proteins, 2007. 67(3): p. 661-70.
Ziolkowska, N.E., et aL, Domain-swapped structure of the potent antiviral
protein griffithsin and its mode of carbohydrate binding. Structure, 2006.

14(7): p. 1127-35.
Ziolkowska, N.E., et aL, Crystallographic studies of the complexes of
antiviral protein griffithsin with glucose and N-acetylglucosamine. Protein
Sci, 2007.16(7): p. 1485-9.
Giomarelli, B., et aL, Recombinant production of anti-HIV protein,
griffithsin, by auto-induction in a fermentor culture. Protein Expr Purif,
2006. 47(1): p. 194-202.
O'Keefe, B.R., et aL, Scaleable manufacture of HIV-1 entry inhibitor
griffithsin and validation of its safety and efficacy as a topical microbicide
component. Proc Natl Acad Sci USA, 2009.106(15): p. 6099-104.
Montefiori, D.C., Evaluating neutralizing antibodies against HIV, SIV, and
SHIV in luciferase reporter gene assays. Curr Protoc Immunol, 2005.
Chapter 12: p. Unit 12 11.
Anderson, N.L., et aL, The human plasma proteome: a nonredundant list
developed by combination of four separate sources. Mol Cell Proteomics,

2004.3(4): p. 311-26.

88

95.

96.
97.
98.

99.
100.
101.
102.
103.

104.
105.
106.

107.

108.
109.

110.

111.

Anderson, N.L. and N.G. Anderson, The human plasma proteome: history,
character, and diagnostic prospects. Mol Cell Proteomics, 2002. 1 (11): p.
845-67.
Garbett, N.C., et aL, Differential scanning calorimetry of blood plasma for
clinical diagnosis and monitoring. Exp Mol Pathol, 2009. 86(3): p. 186-91.
Garbett, N.C., et aL, Interrogation of the plasma proteome with differential
scanning calorimetry. Clin Chem, 2007. 53(11): p. 2012-4.
Fish, D.J., et aL, Statistical analysis of plasma thermograms measured by
differential scanning calorimetry. Biophys Chem, 2010. 152(1-3): p. 18490.
Chaires, J.B., Calorimetry and thermodynamics in drug design. Annu Rev
Biophys, 2008. 37: p. 135-51.
Garbett, N.C., et aL, Calorimetry outside the box: a new window into the
plasma proteome. Biophys J, 2008. 94(4): p. 1377-83.
Zhou, M., et aL, An investigation into the human serum "interactome".
Electrophoresis, 2004. 25(9): p. 1289-98.
Garbett, N.C., et aI., Calorimetric analysis of the plasma proteome. Semin
Nephrol, 2007. 27(6): p. 621-6.
Fung, K. Y., et aL, A comprehensive characterization of the peptide and
protein constituents of human seminal fluid. Prostate, 2004. 61 (2): p. 17181.
Shaw, J.L., C.R. Smith, and E.P. Diamandis, Proteomic analysis of human
cervico-vaginal fluid. J Proteome Res, 2007. 6(7): p. 2859-65.
Owen, D.H. and D.F. Katz, A vaginal fluid simulant. Contraception, 1999.
59(2): p. 91-5.
Owen, D.H. and D.F. Katz, A review of the physical and chemical
properties of human semen and the formulation of a semen simulant. J
Androl, 2005. 26(4): p. 459-69.
Fikkert, V., et aL, env chimeric virus technology for evaluating human
immunodeficiency virus susceptibility to entry inhibitors. Antimicrob Agents
Chemother, 2002. 46(12): p. 3954-62.
Wei, X., et aL, Antibody neutralization and escape by HIV-1. Nature, 2003.
422(6929): p. 307-12.
Platt, E.J., et aL, Effects of CCR5 and CD4 cell surface concentrations on
infections by macrophage tropic isolates of human immunodeficiency virus
type 1. J Virol, 1998.72(4): p. 2855-64.
Wei, X., et aL, Emergence of resistant human immunodeficiency virus type
1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob
Agents Chemother, 2002. 46(6): p. 1896-905.
Balzarini, J., et aL, Profile of resistance of human immunodeficiency virus
to mannose-specific plant lectins. J Virol, 2004. 78(19): p. 10617-27.

89

APPENDIX

List of Abbreviations

GRFT

Griffithsin

HIV

Human Immunodeficiency Virus

HCV

Hepatitis C Virus

SARS

Severe Acute Respiratory Syndrome

Asn

Aspargine

Ser

Serine

Thr

Threonine

ER

Endoplasmic Reticulum

DNA

Deoxyribonucleic Acid

HAART

Highly Active Anti Retroviral Therapy

PBS

Phosphate Buffered Saline

CBC

Complete Blood Count

BSA

Bovine Serum Albumin

SDS

Sodium Dodecyl Sulfate

PAGE

Polyacrylamide Gel Electrophoresis

PVDF

Polyvinylidene Fluoride
90

CAPS

N-cyclohexyl-3-aminopropanesulfonic acid

NFDM

Nonfat Dry Milk

WBC

White Blood Cell

Ne

Neutrophils

Ly

Lymphocytes

Mo

Monocytes

Eo

Eosinophils

Ba

Basophils

RBC

Red Blood Cells

Hb

Hemoglobin

HCT

Hematocrit

MCV

Mean Corpuscular Volume

MCH

Mean Corpuscular Hemoglobin

MCHC

Mean Corpuscular Hemoglobin Concentration

RDW

Red Cell Distribution Width

MPV

Mean Platelet Volume

ALB

Albumin

ALKP

Alkaline Phosphatase

AMY

Amylase

DAPI

4' ,6-diamidino-2-phenylindole

PHA

Phytohemagglutinin

ANOVA

Analysis of Variance

DSC

Differential Scanning Calorimetry
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CO-IP

Co-Immunoprecipitation

BCA

Bicinchoninic Acid

BGG

Bovine Gamma Globulin

NLGS

N-Linked Glycosylation Site
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